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ABSTRACT 
Background: Vitamin D deficiency is a concern in the US. Association between vitamin D 
status and metabolic syndrome (MetS), insulin resistance (IR), and inflammation is unclear in 
children. 
Objective: The relationship between serum vitamin D and MetS, C-reactive protein (CRP), and 
Homeostatic Model Assessment-IR (HOMA-IR) was investigated.  
Design: Data from 3 cycles of National Health and Nutrition Examination Survey, 2001-2006 
for 3700 (1820, boys; 1880, girls) children and adolescents, aged 12-17 y were used to assess 
prevalence of vitamin D deficiency (<20 ng/mL) and association between serum vitamin D and  
prevalence of MetS, various components of MetS, CRP, and HOMA-IR using multivariate 
regression models.  
Results: Overall, prevalences of MetS and vitamin D deficiency were 6.1% and 30.5%, 
respectively. Prevalence of vitamin D deficiency was higher in girls (52%), blacks (74%), non-
supplement users (50%), persons who were examined in winter (56%), and persons in the low 
poverty income ratio group (57%) compared to their counterparts. Serum vitamin D was 
inversely associated with waist circumference (P<0.001), systolic blood pressure (P=0.009), and 
HOMA-IR (P=0.003) and positively associated with HDL-cholesterol (P<0.001). Children with 
lowest serum vitamin D are at increased risk for MetS (P=0.04; OR 2.26; 95% CI: 1.11, 4.61). 
Serum vitamin D was not related to CRP (P<0.10).   
Conclusions: Children with poor vitamin D status are at increased risk for MetS and IR. Because 
of negative health outcomes associated with MetS and poor vitamin D status when existed 
 
 
 
 
individually or in combination, early detection and intervention of these conditions are 
paramount, especially in children.   
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CHAPTER I 
INTRODUCTION             
Health concerns associated with low serum vitamin D are on the rise in children 
and adolescents. Vitamin D is required not only for bone health 
1
 but also plays a role in a 
range of ailments such as autoimmune disease,
2, 3
 cardiovascular disease (CVD), 
4-6
 type 
2 diabetes mellitus (T2DM),
6
 hypertension,
7
 depression,
8, 9
 and certain types of cancer 
10
. 
Vitamin D deficiency is widespread in the US. There is inconsistency is defining vitamin 
D status using serum vitamin D concentration with vitamin D deficiency being defined at 
<11ng/mL,
11, 12
 <15ng/mL
13, 14
 or 20 ng/mL in different studies.
15-17
 Recently, the 
prevalence of vitamin D deficiency (<15 ng/mL) and vitamin D insufficiency (15-29 
ng/mL) was found to be 9% and 61% respectively in children and adolescents.
14
 
Suboptimal circulating concentrations of serum vitamin D have been linked to 
metabolic syndrome (MetS),
18, 19
 cardiometabolic risk factors 
14
 and insulin resistance 
(IR).
20
 MetS is an established risk factor for CVD and T2DM.
6
 While there is a lack of 
consistent criteria in identifying MetS given that various organizations have provided 
different working definitions, the National Cholesterol Education Program Adult 
Treatment Panel III (NCEP-ATP III) definition is most widely used in the US. The 
prevalence of MetS increased among adolescents from 6.4% in the National Health and 
Nutrition Examination Survey (NHANES) 1999-2000 to 8.6 % in NHANES 2001-2006
2 
 
 
 
. 
21-23
 Obesity and IR are the underlying cause of MetS. 
24-26
 IR is known to contribute to 
the pathogenesis of T2DM.
20, 27
 Vitamin D reduces the risk for T2DM by preserving 
insulin secretion and increasing insulin sensitivity. 
20, 27, 28
 However, epidemiological 
evidence relating vitamin D status with IR and glucose homeostasis is not consistent. 
27-32
  
Recently, vitamin D has been linked to inflammation through the activation of 
vitamin D receptors (VDRs) on inflammatory cells.
16
 C-reactive protein (CRP) is a 
predictor of elevated inflammation, 
33, 34
 which has been linked with increased risk for 
CVD, 
35, 36
 obesity, 
32, 37
 and MetS.
33, 38, 39
 However, no epidemiological studies have 
investigated the association between vitamin D and inflammation using CRP as a marker.  
Furthermore, few nationally representative studies investigated the relationship 
between vitamin D, MetS and its individual components, but did not include the 
association between vitamin D with inflammation and IR.
14, 18
 In addition, the inverse 
association between serum vitamin D and IR has been confirmed in adults, but similar 
studies on children and adolescents are lacking. Due to clinical evidence confirming the 
presence of VDRs on pancreatic β cells 1 and inflammatory cells,40 we suggest the 
plausible role of vitamin D in CVD, inflammation, and IR and hypothesize that an 
inverse association exists between serum vitamin D concentration and MetS, CRP, and 
IR. Therefore, we investigated the association between serum vitamin D concentrations 
and prevalence of MetS, individual components of MetS, CRP, and IR in children and 
adolescents from nationally representative sample surveys of the US population.
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CHAPTER II  
 
REVIEW OF LITERATURE 
VITAMIN D  
SYNTHESIS, METABOLISM & SOURCES 
Vitamin D, a lipophilic vitamin, is obtained primarily upon exposure to ultra 
violet radiation of sunlight.
1, 41
 Vitamin D precursors, 7-dehydrocholesterol in the skin is 
converted to vitamin D3. The hydroxylation of vitamin D3 results in the formation of 
vitamin D (25-hydroxyvitamin D) in the liver. Further vitamin D is converted to its active 
metabolite 1,25-dihydroxyvitamin D (1,25 (OH)2D) or calcitriol by 1α-hydroxylase in the 
kidney.
1
 Calcitriol is involved in regulating calcium homeostasis.
1
 
There are limited natural dietary sources of vitamin D. A few foods such as fatty 
fish (mackerel, salmon, and sardines), cod liver oil, liver, and egg yolk contain vitamin D. 
1, 6
 In addition, vitamin D is found in fortified foods such as milk, yogurt, margarine, 
infant formulas, breakfast cereals, orange juice,
42
 enriched rice, corn meal products, 
noodle products and macaroni products. 
1, 43
 Fortified milk (62%) and breakfast cereals 
(17%) are the main food sources of vitamin D in 1-5y old children.
44
 Less than 10% of 
vitamin D is obtained from other foods and supplement sources. 
45
 
FUNCTIONS OF VITAMIN D  
Vitamin D performs multitude of biological functions in the body. It regulates 
calcium and phosphorus homeostasis by enhancing calcium and phosphorus absorption in 
the gut and promoting bone mobilization.
1, 16, 41
 The functions of vitamin D are mediate
4 
 
 
 
through VDRs.  Once the vitamin D enters the nucleus of the cell, it binds with the 
VDRs, and together they modulate gene expression at the cellular level.
1
 VDRs are 
transcription factors expressed in most tissues including the skeletal muscle, vascular 
smooth muscle, osteoblasts, endothelium, cardiomyocytes, activated macrophages, 
pancreatic β-cells. VDRs are also mapped in various organs systems including the small 
intestine, skin, heart, brain, breast, gonads, and prostate gland. 
1, 41
 In addition to the role 
of vitamin D in calcium homeostasis, VDRs are also known to stimulate insulin 
production 
1
 and modulate immune function. 
16, 46, 47
 
VITAMIN D STATUS & RECOMMENDATIONS  
Circulating serum vitamin D is used as a marker of vitamin D status because it 
reflects the total vitamin D production from  endogenous and exogenous sources and has 
a longer half life than calcitriol.
1, 16, 48
 Vitamin D deficiency was defined at serum vitamin 
D concentration <11 ng/mL (27.5 nmol/L) by the Institute of Medicine.
12
  Recently, the 
same agency suggested serum vitamin D concentrations between 20-30 ng/mL as 
adequate to maintain bone health. Previous studies have demonstrated effects of vitamin 
D deficiency at serum vitamin D concentrations higher than 11 mg/mL.
11
  The most 
consistent criteria used to categorize vitamin D in children are <20 ng/mL, 20-30 ng/mL, 
and ≥30 ng/mL for deficiency, insufficiency, and sufficiently, respectively.15, 16, 44 
However, Forouhi et al 
30
 classified vitamin D status in 4 categories: sufficiency (≥30 
ng/mL or ≥75 nmol/L), hypovitaminosis D (<30 ng/mL or <75 nmol/L), insufficiency 
(<20 ng/mL or <50 nmol/L), and classical deficiency (<10 ng/mL or <25 nmol/L). Some 
investigators have also considered serum vitamin D deficiency concentrations ≤15ng/mL
5 
 
 
 (≤37.5 nmol/L) and >20 ng/ml (>50 nmol/L) to define deficiency and sufficiency, 
respectively.
13, 14
 There is ambiguity in defining vitamin D status. 
Excess serum vitamin D concentration is also undesirable. Serum vitamin D 
concentrations ≥80 ng/mL (200 nmol/L) are regarded as the upper limit of serum vitamin 
D.
41
 Costello 
16
 reported vitamin D concentrations >200 ng/mL (>500 nmol/L) is 
considered potentially toxic.  
Numerous factors such as skin pigmentation (melanin), excessive use of 
sunscreen, nature and amount of clothing, geographical location or latitude, season, and 
age affect vitamin de novo vitamin D synthesis in dermis. 
31, 44, 49, 50
 Although some 
investigators found that the prevalence of vitamin D deficiency was higher in children 
with darker skin pigmentation than those with lighter skin pigmentation,
44, 51
 Cole et al 
44
 
found that skin pigmentation did not significantly predict vitamin D status. Clemens et al 
52
 found that non-Hispanic white need 5 to 10 times lesser sun exposure to produce serum 
vitamin D as compared to non-Hispanic black. Season and geographical location affects 
synthesis of vitamin D in the skin. Vitamin D deficiency has been found more prevalent 
in winter than in summer and at higher latitudes than at lower latitudes.
51
 
43
 Webb et al 
53
 
reported endogenous vitamin D synthesis was reduced in persons living above 35° 
latitude in winter.  
The Food and Nutrition Board  of the National Academy of Sciences 
recommended 200 IU/d as the adequate intake of vitamin D for children to maintain 
serum vitamin D concentrations >11 ng/mL (27.5 nmol/L).
12
 The American Academy of 
Pediatrics, a non-profit professional organization recommended 400 IU/d of vitamin D 
supplementation for children and adolescents that are unable to get adequate exposure to 
6 
 
 
sunlight or are unable to consume at least 500 mL of fortified milk daily.
54
 However, 
with the failure to reach minimum serum vitamin D concentration of 20 ng/mL, the 
Institute of Medicine recently revised the recommended dietary allowance (RDA) and 
upper intake level of vitamin D in children and adolescents to 600 IU/d and 4000 IU/d, 
respectively. 
55
 
 VITAMIN D INSUFFICIENCY AND DEFICIENCY  
Vitamin D insufficiency and deficiency in children is an emerging public health 
concern in the US. Suboptimal vitamin D status hampers bone mineralization. Vitamin D 
deficiency prevents children from acquiring appropriate peak bone mass and attaining 
adequate height.
1
 Vitamin D deficiency weakens the collagen matrix of bones leading to 
increased risk of bone fractures. Low serum vitamin D causes secondary 
hyperparathyroidism, which in turn decreases intestinal phosphorous absorption, resulting 
in impaired bone mineralization. Children develop rickets, adults develop osteomalacia 
from deranged mineralization of bones. 
1, 41, 56
 
It is estimated that 61% of children and adolescents are at risk for vitamin D 
insufficiency (15-29 ng/mL) in the US.
14
 Using a definition of vitamin D deficiency <15 
ng/mL, Kumar et al 
14
 found 9% of children 1-21 y old were vitamin D deficient in 
NHANES 2001-2004. A review of 11 studies on healthy US children revealed that 
prevalence of hypovitaminosis ranged from 15 to 78%. Low serum vitamin D 
concentrations were found in older children, in those with higher body mass index (BMI), 
in blacks, or in those measured in winter season.
43
 In this review, vitamin D deficiency 
and insufficiency were defined as having serum vitamin D concentrations between 5 and 
12 ng/mL and 10 and 32 ng/mL, respectively.  Looker et al 
51
 assessed serum vitamin D 
7 
 
 
concentrations in adolescents and adults (aged ≥12 y) from NHANES III (1988-1994). 
They categorized the study sample into 2 groups based on the season of blood sample 
collection for measurement of serum vitamin D concentrations. The need for 
categorization into 2 such groups was due to NHANES survey design that involved 
collection of blood sample from a mobile examination center  (MEC) during summer 
from northern latitudes (range 25-47°N) and during the winter from southern latitudes. In 
the group examined during winter (lower latitude), vitamin D deficiency (<17.5 nmol/L) 
and vitamin D insufficiency (<37.5-62.5 nmol/L) was <1% and 25-57%, respectively. In 
another study on NHANES III, Saintonge et al 
11
 investigated serum vitamin D in 12-19 y 
adolescents using vitamin D deficiency first as <11 ng/mL and then as <20 ng/mL. The 
investigators found vitamin D deficiency changed from 2% to 14% upon changing the 
cutoff. The risk of vitamin D deficiency was significantly higher in women, non-Hispanic 
black, and overweight adolescents as compared to their counterparts.  
Other studies investigated the prevalence of vitamin D deficiency in both northern 
and southern parts of the US. In the south eastern US, Cole et al 
44
found 23% of children 
aged 1-5 y old of low-income families were deficient in vitamin D (≤ 20 ng/mL). The 
researchers found 73.6% of children had serum vitamin D concentrations <30 ng/mL. In 
the northern US (latitude 42° N), Gordon et al 
13
 found 24% (n = 74) of 11-18 y old 
children were deficient (≤15 ng/mL) and 42% (n = 129) were insufficient (< 20 ng/mL) 
in serum vitamin D.  
METABOLIC SYNDROME  
A growing body of evidence suggests that suboptimal vitamin D concentrations 
are linked with an increasing number of health conditions such as MetS. Previously 
8 
 
 
known as Syndrome X 
57
 or Insulin Resistance Syndrome.
58
 MetS is a constellation of 
factors that link obesity, hypertension, IR, T2DM, and CVD.
59
 The World Health 
Organization (1998),
60
 the European Group for the study of IR (EGIR) (1999),
61
 National 
Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) (2001),
62
 and 
the International Diabetes Federation (IDF) (2005) 
63
 have established definitions for the 
diagnosis of MetS.  
Of the numerous MetS definitions, the NCEP-ATP III is commonly used in 
research. According to this definition, the presence of at least 3 of the following 5 
confirms having MetS for adults: WC  ≥40 inches in men or ≥35 inches in women, serum 
triglycerides ≥150 mg/dL, serum high-density lipoprotein cholesterol (HDL-c) <40 
mg/dL for men or <50 mg/dL for women, high BP >130/85 mm Hg, and fasting plasma 
glucose >100 mg/dL.
62
  
There is no universally accepted definition of MetS in children and adolescents. 
Investigators have adapted the adult MetS definition for pediatric population.
22, 64
 The 
modified MetS definition proposed by Cook et al 
22
 includes an individual meeting 3 of 
the 5 following criteria: (1) WC ≥90th percentile for age and sex, (2) triglycerides 
≥110mg/dL (1.24 mmol/L), (3) HDL-c ≤40 mg/dL (1.03 mmol/L), (4) either systolic 
blood pressure (SBP) or diastolic blood pressure (DBP) ≥90th percentile for age, sex, and 
height, and (5) fasting glucose concentration  ≥110 mg/dL (5.55 mmol/L). Ferranti et al 64 
proposed a modified criteria for MetS in children. Children and adolescents were 
classified with having MetS if they met at least 3 or more of the following: (1) fasting 
triglycerides ≥100 mg/dL (1.1 mmol/L),  (2) HDL-c <50 mg/dL (1.3 mmol/L), except in 
boys aged 15-19 y, in whom the cut off was <45 mg/dL (1.2 mmol/L), (3) fasting glucose 
9 
 
 
≥110 mg/dL (6.1 mmol/L), (4) waist circumference > 75th percentile for age and gender, 
and (5) SBP > 90
th
 percentile for gender, age, and height or use of antihypertensive 
medications. A more recent modified NCEP-ATP III pediatric MetS criteria proposed by 
Ford et al 
65
 required that children and adolescents met 3 of the following: (1) triglyceride 
concentration  ≥110 mg/dL, (2) HDL-c ≤40 mg/dL, (3) WC ≥ 90th percentile (sex-
specific), (4) glucose concentration  ≥100 mg/dL, and (5) SBP or DBP ≥90th 
percentile
 
(age, height, and sex-specific).  
PATHOPHYSIOLOGY OF METABOLIC SYNDROME  
Evidence suggests obesity, particularly visceral obesity is an important 
characteristic of the MetS 
23, 24, 59, 66
. Adipose tissue is not only an energy reservoir, but 
also an endocrine organ that secretes inflammatory adipocytokines and all components of 
the renin-angiotensin system (RAS).
59
 The RAS regulates BP and blood volume 
homeostasis and excessive RAS stimulation can lead to hypertension.
67, 68
 The RAS is 
upregulated in obesity.
66
 Adipose tissue secretes adipocytokines such as leptin, resistin, 
interleukin (IL)-6, plasminogen activator inhibitor-1, and tumor necrosis factor (TNF)-
α.24, 66 Elevated concentrations of IL-6 and TNF-α stimulate the production of acute 
phase protein called CRP in the liver.
35, 59
 Higher circulating CRP concentrations indicate 
low-grade systemic inflammation and along with elevated pro-inflammatory cytokines, 
CRP contribute to the development of atherosclerotic plaques.
69, 70
 Thus, increase in 
adiposity is likely to trigger a cascade of events that includes activation of the RAS and 
increased secretion of pro-inflammatory adipocytokine leading to IR s causing 
atherogenic dylipidemia , systemic inflammation through increased secretion  of 
inflammatory marker CRP, and decreased insulin sensitivity resulting in increased insulin 
10 
 
 
resistance 
24, 71
. Other factors such as the oxidative stress, heredity, and lifestyle factors 
also contribute to the development of MetS.
59
 Hence, there exists a complex relationship 
between obesity, IR and various components of MetS. 
PREVALENCE OF METABOLIC SYNDROME 
The increasing prevalence of MetS in children and adolescents has become a 
public health concern.
71
 Epidemiological studies using the NCEP-ATP III definition have 
found the prevalence of MetS in NHANES vary from 4.2 to 12.7% 
18, 21-23, 39
. Cook et al 
22
 reported a prevalence of MetS in 4% adolescents and a prevalence of 30% in 
overweight adolescents using the data from the NHANES III (1988-1994). Using the 
modified MetS definition proposed by Cook et al, 
22
 Duncan et al 
21
 found the prevalence 
of MetS further increased to 6.4% in adolescents (n = 991) in NHANES 1999-2000.  In 
the same data, they found that the prevalence of MetS was 32.1% in overweight 
adolescents. DeFerranti et al 
64
 compared the prevalence of MetS in NHANES 1988-1994 
with those in NHANES 1999-2000 in adolescents. They found that the prevalence of 
MetS increased from 9.2% in NHANES 1988-1994 to 12.7% in NHANES 1999-2000. 
An assessment of MetS in 2456 adolescents (12-19 y) in a more recent NHANES (2001-
2006) using the modified MetS definition proposed by Ford et al,
65
 Johnson et al 
23
 
reported a prevalence of MetS was 8.6% overall and 28.7% in overweight adolescents. 
The prevalence of MetS differed by age and race. The prevalence of MetS was more 
common in men than in women 
21-23, 72
 and is more common in Mexican-Americans than 
in non-Hispanic whites and non-Hispanic blacks. 
22, 64
 
 
 
11 
 
 
VITAMIN D, METABOLIC SYNDROME AND OBESITY 
It has been reported that serum vitamin D concentrations decrease with increasing 
body weight or BMI.
11, 73, 74
  Numerous mechanisms have been proposed for low serum 
vitamin D concentrations in obese individuals. One mechanism is the sequestering of 
vitamin D in adipose tissue leading to low circulating vitamin D concentrations decreases 
its bioavailability. 
73, 74
 Worstman et al 
74
 suggested increased vitamin D storage with 
increase in adipose tissue, although they found no difference in the endogenous synthesis 
of vitamin D and vitamin D precursor (7-dehydrocholesterol) between obese and non-
obese people. This negates the theory that obese people could possibly have lesser 
vitamin D precursors  in the skin, which could result in less vitamin D production than 
that in their non-obese counterparts. Another theory is whether there is a difference in the 
way obese people utilize vitamin D production either through from skin or oral route. 
Wortsman et al 
74
 investigated obese individuals‟ serum vitamin D concentrations from 
the skin as compared from an oral route and intestinal absorption in obese compared to 
non-obese subjects. The investigators reported that after a 24 hr sunlight exposure, there 
was a 57% lesser increase in serum vitamin D concentrations in obese compared to non-
obese individuals.  This suggests that the release of vitamin D may be affected in older 
persons. 
In children, WC is associated with visceral adiposity, while BMI is more likely to 
predict subcutaneous body fat.
75
 A BMI percentile between 85
th
- 95
th
 percentiles is 
considered as overweight, while a BMI ≥95th percentile is considered as being obese 21 
(CDC chart) for children. Szmitko et al 
36
 suggested that WC and skinfold thickness are 
independent predictors of MetS in early adulthood. Increased risk of vitamin D 
12 
 
 
deficiency was found in overweight adolescents as compared with normal-weight 
adolescents. Tangorra et al 
73
 investigated the prevalence of vitamin D deficiency (<20 
ng/mL) and components of MetS in 217 obese children, aged 7-18 y old. Insulin 
sensitivity was calculated by the quantitative insulin sensitivity check index (QUICKI). 
The prevalence of vitamin D deficiency was 55.2% in obese children. They found that 
serum vitamin D was inversely related with BMI and positively related with HDL-c. 
They did not investigate the association between serum vitamin D and season, exposure 
to sunlight, season, race-ethnicity, diet or exercise. Consistent with previous studies, the 
researchers reported that obesity is a risk factor for vitamin D deficiency and that vitamin 
D deficiency more prevalent in obese children than in non-obese children.
11, 74
 
There is emerging evidence that low serum vitamin D concentration is associated 
with the development of CVD and mortality.
4, 5
 An inverse association between the 
prevalence of MetS and vitamin D status has been established. 
19, 76
 Also, low serum 
vitamin D concentrations have been associated with various components of MetS. Maki 
et al 
4
 found low serum vitamin D independently associated with MetS and with HDL-c 
in 257 men and women.
4
 Ford et al 
19
 reported an inverse association between vitamin D 
and MetS, abdominal obesity, hyperglycemia, and  hypertriglyceridemia in NHANES III. 
Reis et al 
76
 investigated the association of serum vitamin D and PTH with MetS in adults 
(≥20 y) in NHANES 2003-2004.  They found a significant inverse association between 
serum vitamin D and prevalences of MetS independent of BMI, parathyroid hormone, 
and total calcium intake. Reis et al 
18
 investigated the association between serum vitamin 
D and cardiometabolic risk factors in 3577 adolescents in NHANES 2001-2004. Using 
the NCEP-ATP III definition modified by Cook et al 
22
 found that low serum vitamin D 
13 
 
 
was significantly associated with MetS and components of the MetS such as elevated BP 
and elevated fasting glucose.  
In another study using the NHANES 2001-2004 data, Kumar et al 
14
 found serum 
vitamin D deficiency (<15 ng/mL) was significantly associated with elevated BP and 
with depressed HDL-c in 1-21 y old children and adolescents. They found only 4% of the 
children had taken 400 IU/d of vitamin D in the month prior to the data collection. 
Alberti et al 
71
 reported that individuals with MetS are twice as likely to develop CVD 
over the next 5-10 y as compared with individuals without MetS. Thus, MetS can lead to 
an atherogenic profile and increase the risk for CVD. 
VITAMIN D, METABOLIC SYNDROME, AND BLOOD PRESSURE 
A newly recognized role of vitamin D is its ability to regulate BP by inhibiting 
renin gene expression.
77
 Renin is an enzyme and a key component of the RAS. The RAS, 
known to regulate BP and blood volume 
68
, is upregulated in obesity.
66
 This leads to 
sodium retention in the kidney.
66
 All components of the RAS are produced in the adipose 
tissue.
78
 For instance, angiotensin receptors are expressed in adipocytes.
79
 Studies have 
suggested that hypertension is caused by many interrelated factors such as disrupted lipid 
metabolism, activation of the RAS, and hyperleptinemia. 
66, 68
 Morse et al 
66
 reviewed 
literature on different components related to hypertension and suggested that excess 
weight gain is the underlying cause of elevated BP. Increased adiposity triggers increased 
activity of the sympathetic nervous system (SNS), RAS, and increased adipocytokine 
production . It has also been reported that IR from hyperinsulinemia contributes to the 
development of hypertension.
58
 
14 
 
 
Elevated BP is one of deranged abnormalities of the MetS.
66, 68
 Recent studies 
have implicated low serum vitamin D concentrations as a risk factor for elevated 
BP.Vitamin D affects BP through regulation of the RAS, as well as its calcium 
mobilizing properties.
80-82
 Zittermann et al 
68
 postulated that vitamin D may affect 
vascular smooth muscle, cell proliferation, inflammation, vascular calcification, and BP 
through the RAS 
68
. Animal studies show that vitamin D is an important regulator of the 
RAS system and that 1,25-dihydroxyvitamin D suppresses renin gene expression.
67
 
Disruption of the VDR gene leads to elevated renin production, cardiac hypertrophy, and 
elevated BP in mice.
83
  
Epidemiological studies have investigated the relationship between serum vitamin 
D concentrations and BP. In the Framingham Offspring longitudinal study, Wang et al 
48
 
assessed CVD risk and found twice the risk for CVD events in vitamin D deficient 
individuals that had hypertension than those that did not have hypertension. The authors 
also reported 28% of the participants had vitamin D deficiency (<15 ng/mL) and 
confirmed evidence that vitamin D deficiency is a risk factor for CVD. Judd et al 
7
 found 
obese children with serum vitamin D <20 ng/ml were found to have significantly higher 
SBP than obese children with serum vitamin D ≥20 ng/mL, in NHANES III (1988-1992). 
The investigators classified BP into 5 categories with a sixth category added to 
distinguish participants with normal SBP (<110 mm Hg) from those with high-normal 
SBP (110-119 mm Hg). In contrast, Maki et al 
4
 did not find an association between 
serum vitamin D and BP.  They suggested that such an association was not found because 
a majority of the subjects in the study were vitamin D sufficient (>30 ng/mL) and were 
15 
 
 
non-Hispanic white. In order to reduce elevated BP, studies suggest vitamin D 
supplementation 
7, 48
 and weight loss, especially in obese individuals.
84
  
INSULIN RESISTANCE  
Pancreatic β-cells promote the uptake, utilization, and storage of glucose by liver 
and peripheral tissues by producing insulin. The cells also express VDRs and1α-
hydroxylase which is required for the conversion of vitamin D to 1,25(OH)2D. 
85
 
Decreased insulin sensitivity or increased IR, a physiological state that results from 
impaired ability of plasma insulin to control altered glucose metabolism. It has been 
found that IR can also be present in individuals independent of excessive adiposity.
72
 
However, in the obese state, higher secretion of adipocytokines can lead to hypertension, 
endothelial dysfunction, and deranged lipid metabolism.
58
 Thus, IR precedes the 
development of MetS 
24, 66
 and is associated with increased risk for T2DM and CVD 
15, 24
.  
IR and pancreatic β-cell function are measured both by direct and indirect 
methods. The euglycaemic insulin clamp is considered the gold standard because this 
method is used to measure the IR directly and is regarded as highly sensitive.
86, 87
 Other 
indirect indices such as the Homeostatic Model of IR (HOMA-IR) and the QUICKI are 
also used to measure IR and insulin sensitivity. The HOMA-IR method, based on fasting 
glucose and insulin concentrations, is determined using a mathematical model.
88
 The 
value of IR is calculated as the product of insulin concentration (µU/mL) and fasting 
glucose concentration (mg/dL) divided by 405.
88
 Unlike the euglycaemic insulin clamp 
method, the HOMA-IR is a less invasive and labor-intensive method. This method is 
widely used for the measurement of IR in large epidemiological studies.
87, 89
 On 
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evaluating 55 hospitalized Japanese patients with T2DM before and after a diet and 
exercise therapy treatment for 6 weeks, Katzuki et al 
87
 found HOMA-IR to be useful in 
identifying IR. The investigators came to this conclusion after having found significant 
correlation between HOMA-IR and the euglycemic clamp both before and after treatment 
in T2DM patients. Several other epidemiological studies have shown HOMA-IR to be a 
reliable marker of IR. 
32, 88
 
VITAMIN D, METABOLIC SYNDROME, AND INSULIN RESISTANCE 
Vitamin D is proposed to alter insulin action on the adipocyte, affect the release 
of insulin from the pancreatic β-cell, or regulate the RAS. 27, 90 The mapping of VDRs on 
pancreatic β-cells and binding of 1,25 (OH)2D to it in the cell nucleus suggests a 
physiological role of vitamin D in regulating pancreatic β-cells functioning.27 Because 
vitamin D deficiency causes increased renin-angiotensin II expression,
90
 adequate serum 
vitamin D concentrations may help improve insulin sensitivity by preventing increase in 
renin-angiotensin II expression and its resultant stimulation of nuclear factor kappa-light-
enhancer of the activated B cells (NF-kB). 
40, 91, 92
 
Alvarez et al 
20
 summarized the literature related to potential vitamin D influences 
on glucose homeostasis and insulin sensitivity. There is evidence that circulating serum 
vitamin D is inversely associated with IR, and a complex vitamin D action with these 
VDRs in the adipocyte and pancreatic β cell mediates insulin sensitivity and insulin 
secretion. In addition, glucose homeostasis and insulin metabolism are influenced by 
polymorphisms in VDR gene.
20, 89
 Stunff et al 
89
 studied the association of a common 
p110 β single nucleotide polymorphism (SNP) with IR using HOMA-IR in 580 severely 
obese (BMI > 99.6
th
 percentile) and 606 non-obese European children. The investigators 
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identified that the SNP was linked to elevated fasting glucose, insulin, and HOMA-IR 
index. Although the precise mechanism by which genetic factors affect insulin action on 
liver and muscle has not been elucidated, the possibility of targeting genetic VDR 
markers may help drive interventions to prevent development of IR and its progression to 
T2DM in children and adolescents.  
In epidemiological studies, Forouhi et al 
30
 found baseline serum vitamin D 
inversely associated with fasting glucose, fasting insulin, and HOMA-IR in a10-year 
follow up study. Caceres et al 
72
 studied the association between IR and MetS 
components in 61 Bolivian obese children and adolescents (age 5-18y) using the NCEP-
ATP III modified definition. In this sample, the prevalence of MetS and IR were 36% and 
39.4%, respectively.  IR was significantly associated with components of MetS such as 
hypertension and high triglyceride concentrations. A study by Alemzadeh et al 
31
 found 
low vitamin D status associated with increased risk of impaired glucose metabolism, 
independent of body adiposity, in 127 obese children and adolescents (mean age ± SD: 
13.0 ± 3.0 y) living in northern climate (43° N). The investigators found 32.3% of 
vitamin D deficiency overall, with suboptimal vitamin D concentrations (<30 ng/mL) in 
74% of obese subjects. Using the QUICKI, serum vitamin D was directly associated with 
insulin sensitivity. There was overrepresentation of women in the study (62.2%).  
Chiu et al 
28
 investigated the relation of serum vitamin D concentrations to insulin 
sensitivity and β-cell function in 126 healthy adults using both hyperglycemic clamp and 
oral glucose tolerance test and found that hypovitaminosis D was a risk factor for MetS, 
and was directly associated with insulin sensitivity and inversely associated with β-cell 
function. Evliyaoğlu et al 93 evaluated IR using oral glucose tolerance test (OGTT), 
18 
 
 
HOMA-IR, glucose/insulin ratio, and serum lipid profiles in 19 pre-pubertal girls with 
premature pubarche (mean age=6.9 ± 1.7) as compared to 10 age- and Tanner stage-
matched controls (mean age=7.5±1.3) using indirect IR parameters. Using HOMA-IR 
and glucose/insulin ratio methods with 95% CI of 2.96 as the cut off for HOMA-IR, IR 
was found as 42.1% and 31.6%, respectively. Mean baseline insulin and HOMA-IR were 
significantly higher and glucose/insulin ratio was lower in the girls with premature 
pubarche than in the control group. In contrast, Reinehr et al 
32
 did not find a relationship 
between vitamin D, and insulin sensitivity based on the HOMA index in obese children. 
The study was based on a small sample size. The majority of subjects had normal 1,25 
(OH)2D concentrations. These may explain the lack of relation between vitamin D and 
insulin
 
sensitivity.  
Thus, evidence linking vitamin D and IR is equivocal. Adequate serum vitamin D 
concentrations may improve insulin sensitivity and reduce IR.
20, 27
 However, the exact 
mechanism through which vitamin D influences the pathophysiology associated with 
T2DM is not clear.   
VITAMIN D, METABOLIC SYNDROME, & CRP 
The role of CRP, an inflammatory biomarker, in hypertension and CVD has been 
explored recently 
36, 94
. Several epidemiological studies suggest high CRP concentrations 
are associated with increased risk for obesity, hypertension, endothelial dysfunction, 
MetS 
38, 39
, and CVD 
33
. In children, there is evidence that CRP is significantly associated 
with obesity 
33, 34, 37, 39
, and MetS, and components of MetS 
33, 38, 39
.  Oliviera et al 
33
 
investigated the association between CRP and MetS and components of MetS in 407 
overweight and obese Brazilian children. They reported that children with MetS had the 
19 
 
 
most elevated CRP concentrations and that elevated CRP was significantly associated 
with IR and MetS.
33
 Ford et al 
38
 studied low-grade inflammation in 1366 children aged 
12-17 y in NHANES 1999-2000. Significantly higher CRP concentrations (> 3.0 mg/L) 
were found in 38.4% of children with MetS as compared to 10.3% of children without 
MetS. Abdominal obesity was independently associated with CRP.  
To test a hypothesis that an increase in the prevalence of multiple inflammatory 
markers is associated with increase in body weight, Skinner et al 
37
 investigated CRP, 
absolute neutrophil count, and ferritin level in children aged 1-17 y using the data from 
NHANES 1999-2006. They found that obese children, aged 3-5y old, had elevated CRP 
concentrations (>1.0 mg/L). Gillum 
34
 also found that BMI was strongly associated with 
CRP concentrations in 6-11 y old Mexican-American children in the NHANES III. Sesso 
et al 
94
 investigated IL-6 and CRP concentrations in 400 women that developed 
hypertension during 10 y period of follow-up in the Women‟s Health Study. The 
investigators found significantly higher risk of developing hypertension with higher CRP 
concentrations. They concluded that inflammation had a definite role to play in 
identifying individuals at risk for hypertension. DeFerranti et al 
39
 reported that 12-19 y 
old adolescents with MetS had significantly higher CRP concentrations in NHANES 
1999-2000.  
Recent evidence links VDRs with inflammation suggesting a role for vitamin D in 
inflammation. The location of VDRs on inflammatory cells such as the peripheral blood 
mononuclear cells, T-lymphocyte, and macrophages suggests the role of vitamin D in 
mediating immune system response and inflammatory process. 
40
 
68, 95
 But, the exact 
mechanism through which vitamin D deficiency affects CRP is not clear. Sun et al 
40
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confirmed that the expression of various cytokines such as as interleukin (IL)-1, IL-6, IL-
8, and TNF are down-regulated by 1,25(OH)2D and that VDR is involved in the 
inflammatory response pathway through its regulation of the NF-kB. It is plausible that 
central obesity plays an integral role in inflammatory process by triggering the 
inflammatory cascade.  
There are limited data on the relationship between CRP and vitamin D status. In a 
study by Michos et al,
15
 a weak inverse relation between CRP and serum vitamin D was 
found (n = 650). However, this association was not significant after adjusting the analysis 
for BMI. The mechanism through which inflammatory markers such as CRP affects 
vitamin D concentration or vice versa is unclear. Thus, CRP is not only an independent 
predictor of CVD risk 
36
 and marker of low-grade inflammatory state in obesity, 
96
 but 
high CRP concentration indicates inflammation that is likely to contribute to components 
of MetS. Clinical findings make it reasonable to support an anti-inflammatory role of 
vitamin D in immune system, but it is supported by limited epidemiological evidence.  
CONCLUSION 
Newer roles of vitamin D in addition to its function in bone health have 
implications in the development of many chronic diseases. It appears that there is a role 
for vitamin D in adipocytes. Children and adolescents with low vitamin D concentrations 
are at risk for rickets, obesity, MetS, and its related health conditions. Evidence stresses 
the need for standardization of an universally accepted definition for both MetS and 
vitamin D status. Much remains to be learned about the complex role of vitamin D in 
MetS, IR, and inflammation, and the consequences of vitamin D deficiency from 
childhood to adulthood
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CHAPTER III 
SUBJECTS AND METHODS  
     
STUDY DESIGN AND SUBJECTS      
The National Center for Health Statistics (NCHS) of the Centers for Disease 
Control and Prevention (CDC) conducts large nationally representative sample surveys 
known as NHANES on civilian, non-institutionalized US population, using a stratified, 
multistage, probability sample survey design. Data on demographic characteristics, diet, 
and health are collected from personal interviews. Physical examinations and collection 
of blood and urine samples are done in the MEC. Low-income persons, adolescents (12-
19 y), individuals ≥60 y, African Americans, and Mexican Americans were over sampled 
to yield reliable estimates for these groups. The detailed description of the survey 
methods and analytic guidelines are reported elsewhere. 
97
 All NHANES protocols were 
approved by NCHS Ethics Review Board.  
For this study, data on children and adolescents aged 12-17 y from NHANES 
2001-2002 (n = 1905), 2003-2004 (n = 1724), and 2005-2006 (n = 1704) were combined 
into one master database, NHANES 2001-2006. Of 5333 eligible participants, 5186 
completed the interview and the examination components of the survey. Subjects with 
missing values for serum vitamin D (25-hydroxy cholecalciferol or calcidiol) 
concentration and potential confounding variables of MetS were excluded from the data 
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analysis. The study was limited to children over the age of 17 because fasting plasma 
glucose and serum insulin was measured only in NHANES participants over the age of 
DESCRIPTION OF STUDY VARIABLES   
Potential confounding variables included in the data analysis were age, sex, race-
ethnicity, BMI, poverty income ratio (PIR), time of examination, and use of supplements. 
The age of the subjects was categorized into12-14 y and 15-17y age groups. Race-
ethnicity was reported as non-Hispanic white, non-Hispanic black, Mexican-American, 
and others (included multiracial). PIR is the ratio of income to the family's appropriate 
poverty threshold, given by the US Census Bureau to define poverty status in accordance 
with Office of Management and Budget (OMB) Statistical Policy Directive14.
100
 PIR 
values were categorized as below poverty (<1.0), middle income (1.0-2.5), and higher 
income (≥2.5).100 In NHANES, data were collected in 2 time periods. In the North, data 
were collected during summer (May 1 - October 31), whilst in the South, data were 
collected during winter (November 1 - April 30). 
Measurements for waist circumference (WC), BMI, systolic blood pressure 
(SBP), and diastolic blood pressure (DBP) measurements were obtained from the 
examination component of NHANES. For children and adolescents aged 12-17 y, WC 
was measured at the high point of the iliac crest at the end of a normal expiration to the 
nearest 0.1 cm by trained personnel. Age- and sex-specific 90
th
 percentiles of WC were 
derived for the study population.  BMI was categorized as normal weight (<85
th
 
percentile) and overweight and obese (≥85th percentile) for age and sex. For each subject, 
up to 4 SBP and DBP measurements were obtained after resting quietly in a sitting 
23 
 
 
 
position for 5 min and determining the maximum inflation level using a mercury 
sphygmomanometer. These values were used to calculate mean BP.
101
 Age- and sex-
adjusted 90
th
 percentile of SBP and DBP measurements were derived. The participants 
who answered „yes‟ to the question “did you use supplements in the past 30 d” were 
regarded as supplement users.  
BIOCHEMICAL MEASUREMENTS 
Blood was collected by venipuncture at MEC according to standard protocol. 
98, 99, 
102
 Serum vitamin D concentrations were determined using the Diasorin RIA kit assay at 
the NCHS, CDC. Serum HDL-C was analyzed using the heparin manganese precipitation 
method in NHANES 2001-2002 and a direct HDL-C immunoassay method in NHANES 
2005-06. Triglyceride was measured enzymatically at Johns Hopkins Hospital, 
Baltimore, MD.  Glucose concentration was determined enzymatically in NHANES 
2001-2002 and with the Hexokinase method in NHANES 2003-2006. To trend the 
fasting glucose data and to be able to compare NHANES 2005-2006 to the NHANES 
2003-2004 glucose data, we used the following glucose regression equation as per NCHS 
guidelines. 
98, 99
   
Y (2003-2004) = 0.9835*X (2005-2006), n=92, r=0.9993, intercept not significant.  
Y (2005-2006) = 0.9815*X (2003-2004) + 3.5707, n=92, r=0.9919. 
Serum insulin was measured with a Pharmacia method in NHANES 2001-2002, 
with a Tosoh immunoenzymometric method in NHANES 2003-04, and with a Mercodia 
ELISA immunoassay method in 2005-2006. The mean for the Tosoh method was ≈ 11% 
lower than the mean for Pharmacia method . To account for the change in laboratory 
measurement procedure, CDC recommended the following linear regression to adjust the 
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NHANES 1999-2002 Pharmacia values when comparing them to NHANES 2003-2004 
values: 
Y (Tosoh) = (1.0027 * Pharmacia) - 2.2934 
Upon adjustment, one observation with negative insulin values was excluded 
from the analysis. To trend the serum insulin data and to be able to compare the 
NHANES 2005-2006 (Mercodia) method to the NHANES 2003-2004 (Tosoh) method, 
we used the following insulin regression equation to compare NHANES 2005-2006 data 
to NHANES 2003-2004 data as per NCHS guidelines: 
 Y (Tosoh) = 1.0526 *X (Mercodia) – 1.5674, n=189, r=0.9870 98, 99 
Both fasting glucose and serum insulin were measured at the Diabetes Diagnostic 
Laboratory, University of Missouri, (Columbia, MO) for NHANES 2001-2004 and at the 
Fairview Medical Center Laboratory, University of Minnesota (Minneapolis, MN) for 
NHANES 2005-2006. IR was assessed using Homeostatic Model Assessment-Insulin 
Resistance index (HOMA-IR) calculated using fasting insulin (µU/mL) × fasting glucose 
(mg/dL)/405 
88
. Serum CRP was measured with latex-enhanced nephelometry method at 
University of Washington, Seattle, WA. 
DEFINITION OF METABOLIC SYNDROME VARIABLES  
The prevalence of MetS in children and adolescents was defined according to the 
modified National Cholesterol Education Program –Adult Treatment Panel III age-
adjusted criteria.
65
 According to these criteria, the presence of at least 3 of the following  
will be regarded as having MetS: (1) WC ≥90th percentile for age and sex, (2) 
triglycerides  ≥110 mg/dL (1.24 mmol/L), (3) HDL-C ≤40 mg/dL (1.03 mmol/L), (4) 
either SBP or DBP  ≥90th percentile for age and sex /use of blood pressure 
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medication/previous diagnosis of BP, and (5) fasting glucose ≥100 mg/dL (5.55 
mmol/L)/current diabetes status/ current insulin use or hypoglycemic medication use. 
STATISTICAL ANALYSIS  
SAS-callable SUDAAN (version 10.0.1) and SAS (version 9.2) statistical 
software packages were used in the data analysis. A 6-year sampling weight and 
secondary sampling units, i.e., Masked Variance Pseudo-PSU and Masked Variance 
Pseudo-Stratum were used to produce statistically reliable estimates and correct for 
unequal probability of selection due to oversampling of certain study subgroups. The 
Taylor Linearization method was used to compute variance estimates assuming a design 
with replacement. Detailed descriptions on sample weights and variance estimation 
methods are provided in the NHANES Analytic Guidelines.
97
 
Combining the data from 3 NHANES cycles (2001-2002, 2003-2004, and 2005-2006) 
provided us more stable estimates of means, percentiles, and prevalence estimates for 
serum vitamin D. The status of vitamin D was classified as deficient, insufficient, and 
sufficient if subjects had serum vitamin D concentrations <20 ng/mL, 20-30 ng/mL, and 
≥30 ng/dL, respectively. Serum vitamin D of subjects was stratified into tertiles. The 
tertile ranges were <19.5 ng/dL, 19.5-26.2 ng/dL, and  ≥ 26.2 ng/dL. The difference in 
proportion of subjects with vitamin D deficiency, insufficiency, and sufficiency was 
determined using Rao-Scott chi-square test. The multivariate- adjusted means and 95% 
confidence interval (CI) for indicators of MetS , HOMA-IR, and CRP across tertiles of 
serum vitamin D concentrations were generated using regression analysis .  
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Association between prevalence of MetS and serum vitamin D concentration was 
analyzed with multivariate-adjusted logistic regression analysis. This analysis included 
sex, age, race-ethnicity, smoking, alcohol, supplement use, timing of examination, BMI, 
and PIR as confounding variables. Non-significant variables such as PIR, time of the 
examination, use of supplements, alcohol use, and smoking were dropped from the 
model. Multivariate-adjusted odds ratios (OR) and 95% CI were calculated for the 
presence of MetS for each serum vitamin D tertile category after adjusting the analysis 
for age, sex, race-ethnicity, and BMI. ORs for tertile 1 and 2 in relation to tertile 3 
(referent category) were compared. Additionally, the association between prevalence of 
MetS in subjects with BMI ≥85th percentile and serum vitamin D was analyzed. 
Individual multivariate linear regression models were developed to ascertain the 
association between serum vitamin D and WC, fasting blood glucose, HDL-C, 
triglyceride, SBP, DBP, CRP, and HOMA-IR. Because the distribution of fasting 
glucose, triglycerides, CRP, and HOMA-IR were skewed, these variables were log-
transformed in the analysis. Multiple comparisons (P < 0.0167) were performed to 
determine significant difference between the adjusted means for serum vitamin D tertiles 
for each indicator of MetS with Bonferroni adjustment after testing the hypothesis with 
unpaired 2-tailed t-test. We determined interactions between vitamin D and confounding 
variables. A P of ≤ 0.05 was considered statistically significant in all analyses.
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CHAPTER IV 
RESULTS         
Sample sizes and health characteristics of the study population are given in Table 
1.  The study population consisted of 49.1% boys and 50.9% girls. Mean age of the 
sample was 14.5 y. Of the 3700 subjects, 61.8% (n = 985) were non-Hispanic white, 
14.6% (n = 1226) were non-Hispanic black, and 17.5% (n = 1333) were 
Hispanic/Mexican American. The subjects were uniformly distributed between 12-14y 
(50.2%) and 15-17y (49.8%) age groups. Approximately 24% of the study population 
reported having taken a supplement in 1 month prior to the survey. The majority of the 
subjects were examined in summer (≈ 59%). Detailed sample sizes and health 
characteristics of study population are reported in Appendix A. 
The prevalence of MetS in12-17 y old children and adolescents in NHANES 
2001-2006 was 6.1% (Table 2). The prevalence of MetS was significantly higher in boys 
than in girls (7.9% vs. 4.3%; P <0.001) and in overweight and obese subjects (BMI ≥85th 
percentile) than in non-overweight subjects (BMI <85
th
 percentile) (39.1% vs. 1.8%; P 
<0.001). Additionally, MetS was significantly different across vitamin D status categories 
(8.7% vs. 6.4% and 3.5%; P <0.001). Detailed descriptive statistics of the prevalence of 
MetS is reported in Appendix B. 
The prevalence of vitamin D deficiency in 12-17 y old children and adolescents in 
NHANES 2001-2006 is presented in Table 3. Of the total study population, 30.5% had 
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vitamin D concentrations <20 ng/mL. Suboptimal serum vitamin D concentrations were 
higher in girls than in boys (51.9% vs. 42.5%), in non-Hispanic black than in multiracial 
ethnicity and Hispanic/Mexican American (73.6% vs. 51.9% and 46.8%), in subjects in 
the PIR <1.0 category than in those in the PIR 1.0-2.5 or ≥2.5 category (57.2% vs. 50.9% 
and 35.3%), in subjects  
Table 1: Sample sizes and health characteristics of 12-17 y old children and 
adolescents in the National Health and Nutrition Examination Surveys (NHANESs) 
2001-2006
1
 
Characteristic Values 
2
 
Sex  
   Boys  
   Girls  
 
1820 (49.1) 
1880 (50.9) 
Race-ethnicity  
   Non-Hispanic white  
   Non-Hispanic black  
   Hispanic/Mexican American  
   Other  
 
985 (61.8) 
1226 (14.6) 
1333 (17.6) 
156 (6.0) 
Age  
   12-14 y  
   15-17 y  
 
1859 (50.2) 
1841 (49.8) 
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Poverty income ratio 
3
 
   <1.0  
   1.0-2.5  
   ≥2.5  
 
989 (17.4) 
1259 (28.8) 
1280 (50.0) 
Time of examination 
4
 
   Summer  
   Winter  
 
1749 (58.9) 
1951 (41.1) 
Use of supplements 
3, 5
 
   Yes  
   No   
 
714 (24.1) 
2984 (75.8) 
Body mass index 
 
  22.3 ± 0.1 
Vitamin D status  
Deficiency (<20 ng/mL) 1748 (30.5) 
Insufficiency (20-30 ng/mL) 1541 (49.8) 
Sufficiency (≥30 ng/mL) 
Positive for metabolic syndrome 
411 (19.7) 
213 (6.1) 
Waist circumference (cm)
 3
 
   Boys  
   Girls 
 
78.6 ± 0.4 
78.2 ± 0.5 
Blood pressure (mm Hg)  
  Systolic 
6
 
  Diastolic 
6
 
 
107.1 ± 0.3 
59. ± 0.4 
HDL-cholesterol  (mg/dL) 
6
 51.4 ± 0.3 
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Fasting triglyceride (mg/dL) 
7
 77.8 ± 1.4 
Fasting glucose (mg/dL) 
7
 93.0 ± 0.4 
Serum insulin (µU/mL) 
7
 10.5 ± 0.2 
C-reactive protein (µg/dL)
 7
  43 ± 0.001 
HOMA-Insulin Resistance 
7, 8
 2.4 ± 0.06 
1
n = 3700, weighted n = 17681659. NHANES 2001-2002, 2003-2004, and 2005-2006 
were combined into one master database, NHANESs 2001-2006.  
2
Values are n and weighted percentages in parentheses or mean ± SE. 
3
Sample sizes are slightly lower due to missing responses.
 
4
The examination was performed during summer (May 1 - October 31) and winter 
(November 1
 
- April 30).
 
5
Participants who took supplements 1mo before the survey was conducted. 
6
Arithmetic means ± SE because data are normal. 
7
Geometric mean ± SE because data are skewed. 
8
Derived using the formula: fasting insulin (µU/mL) × fasting glucose (mg/dL)/405.  
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Table 2: Characteristics of 12-17 y old children and adolescents with metabolic 
syndrome in the National Health and Nutrition Examination Surveys (NHANESs) 
2001-2006
1
 
Characteristic  Prevalence of Metabolic syndrome, n  (%)
2
 P-value
 3
 
All subjects 
Sex  
   Boys  
   Girls 
213 (6.1) 
 
127 (7.9) 
86 (4.3) 
 
<0.001 
 
 
Race-ethnicity  
   Non-Hispanic white  
   Non-Hispanic black  
   Hispanic/Mexican American  
   Other  
 
65 (6.6) 
49 (4.2) 
92 (6.6) 
7 (3.7) 
0.11 
 
 
 
 
Age  
   12-14 y  
   15-17 y  
 
106 (5.9) 
107 (6.3) 
0.74 
 
 
Poverty income ratio 
4
 
   <1.0  
   1.0-2.5  
   ≥2.5  
 
56 (6.5) 
74 (6.4) 
72 (5.6) 
0.67 
 
 
 
Time of examination 
5
 
   Summer  
   Winter 
 
91 (6.7) 
122 (5.2) 
0.18 
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Use of supplements 
4, 6
 
   Yes  
   No   
 
29 (4.2) 
183 (6.6) 
0.01 
 
 
Body mass index 
 4 
  <85
th
 percentile  
   ≥85th percentile  
Vitamin D status 
Deficiency (<20 ng/mL) 
Insufficiency (20-30 ng/mL) 
Sufficiency (≥30 ng/mL) 
 
41 (1.8) 
172 (39.1) 
 
131 (8.7) 
56 (6.4) 
26 (3.5) 
<0.001 
 
 
<0.001 
1
n = 3700, weighted n = 17681659. NHANES 2001-2002, 2003-2004, and 2005-2006 
were combined into one master database, NHANESs 2001-2006. 
2
Metabolic syndrome was defined according to the modified National Cholesterol 
Education Program Adult Treatment Panel III criteria, the presence of at least 3 of the 
following criteria (waist circumference > 90
th
 percentile for age and sex, triglycerides > 
110 mg/dL (1.24 mmol/l), HDL < 40 mg/dL (1.03 mmol/l) for gender, either systolic or 
diastolic blood pressure  >90
th
 percentile for age, sex and height, or use of blood pressure 
medication, and fasting glucose >100 mg/dL (5.55 mmol/l). Values are n and weighted 
percentages in parentheses. 
3
 Significance in Rao-Scott χ2 test. 
4
Sample sizes are slightly lower due to missing responses.
 
5
The examination was performed during summer (May 1 - October 31) and winter 
(November 1
 
- April 30). 
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6
Participants who took supplements 1mo before the survey was conducted.  
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Table 3: Prevalence of vitamin D deficiency in 12-17 y old children and adolescents 
in the National Health and Nutrition Examination Surveys (NHANESs) 2001-2006
1 
 
Characteristic 
Serum vitamin D status  
P-value
2
 Deficiency 
(<20 ng/mL) 
Insufficiency 
(20-30 ng/mL) 
Sufficiency 
(≥30 ng/mL) 
All subjects (n =3700) 
Sex  
   Boys (n =1820) 
   Girls (n =1880) 
Race-ethnicity  
   Non-Hispanic white (n =985) 
   Non-Hispanic black (n =1226) 
   Hispanic/Mexican American (n =1333) 
   Other (n =156) 
1748 (30.5) 
 
773 (42.5) 
975 (51.9) 
 
141 (14.3) 
902 (73.6) 
624 (46.8) 
81 (51.9) 
1541 (49.8) 
 
821 (45.1) 
720 (38.3) 
 
550 (55.8) 
296 (24.1) 
628 (47.1) 
67 (43.0) 
411 (19.6) 
 
226 (12.4) 
185 (9.8) 
 
294 (29.8) 
28 (2.3)   
81 (6.1) 
8 (5.1) 
 
<0.004 
 
 
<0.001 
Age  
   12-14 y (n =1859) 
   15-17 y (n =1841) 
 
869 (46.7) 
879 (47.8) 
 
790 (42.5) 
751 (40.8) 
 
200 (10.8) 
211 (11.5) 
0.91 
Poverty income ratio 
3
 
   <1.0  (n = 989) 
   1.0-2.5 (n =1259) 
   ≥2.5 (n =1280) 
 
566 (57.2) 
641 (50.9) 
452 (35.3) 
 
367 (37.1) 
498 (39.6) 
620 (48.4) 
 
56 (5.7) 
120 (9.5) 
27 (2.1) 
<0.001 
Time of examination 
4
 
   Summer (n =1749) 
 
654 (37.4) 
 
798 (45.6) 
 
297 (17.0) 
<0.001 
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   Winter   (n =1951) 1093 (56.0) 743 (38.1) 114 (5.8) 
Use of supplements 
3, 5
 
   Yes (n =714) 
   No  (n =2984) 
 
247 (34.6) 
1499 (50.2) 
 
360 (50.4) 
1181 (39.6) 
 
107 (15.0) 
304 (10.2) 
<0.001 
Body mass index 
3
 
  <85
th
 percentile(n =3181)  
  ≥85th percentile  (n =491) 
 
1408 (44.3) 
319 (65.0) 
 
1391 (43.7) 
143 (29.1) 
 
382 (12.0) 
29 (5.9) 
<0.001 
1
n = 3700, weighted n = 17681659. NHANES 2001-2002, 2003-2004, and 2005-2006 
were combined into one master database, NHANESs 2001-2006. Prevalence based on 
actual cases. 
2
 Significance in Rao-Scott χ2 test. 
3
Sample sizes are slightly lower due to missing responses. 
4
Examination was performed during summer (May 1 - October 31) and during winter 
(November 1- April 30). 
5
Participants who took supplements 1mo before the survey was conducted. 
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examined in the winter than those examined in the summer (56.0% vs. 37.4%), in non-
supplement users than in supplement users (50.2 vs. 34.6%)and in children with BMI 
≥85th percentile than in children <85th percentile (65.0% vs. 44.3%). Sex, race-ethnicity, 
PIR, time of examination, use of supplements, and BMI were significantly different for 
serum vitamin D concentrations across the 3 categories (P <0.004). Detailed descriptive 
statistics are reported in Appendix C. 
Sample sizes and serum D concentrations for descriptive variables are given in 
Table 4. Sample sizes of girls (51.9%), non-Hispanic black (73.6%), subjects in the 
PIR<1.0 category (57.2%), subjects examined in the winter (56.0%), and in non-
supplement users (50.2%) were higher in the lowest serum vitamin D tertile category 
(tertile 1 <19.5 ng/mL) as compared with the highest serum vitamin D tertile category 
(tertile 3 ≥ 26.2 ng/mL) and as compared to their counterparts. Sex, race-ethnicity, PIR, 
time of examination, use of supplements, and BMI were significantly different for serum 
vitamin D across the tertile categories (P <0.001). Detailed sample sizes of descriptive 
variables according to vitamin D concentration categories can be found in Appendix D. 
The association between serum vitamin D concentrations and prevalence of MetS 
is presented in Table 5. In the multivariate adjusted analysis, serum vitamin D was 
significantly associated with prevalence of MetS (P for trend = 0.04). There was a 
significant trend in the likelihood of having MetS across the serum vitamin D tertile 
categories. The likelihood of children having MetS in the lowest serum vitamin D tertile 
category was 2.26 (95% CI: 1.11, 4.61) compared with subjects in the highest serum 
vitamin D tertile category. Although there was no association between serum vitamin D 
and MetS in children and adolescents with BMI ≥85th percentile (P for trend = 0.33), a 
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trend of increasing likelihood of MetS with decreasing vitamin D concentrations was 
found. Detailed results of the association between serum vitamin D concentrations and 
prevalence of MetS are reported in Appendix E. 
The associations between serum vitamin D concentrations and individual 
components of MetS are presented in Table 6. An inverse association between serum 
vitamin D and WC (P for linear trend <0.001), SBP (P for linear trend = 0.009), and 
HOMA-IR score (P for linear trend = 0.003) and a positive association between serum 
vitamin D and HDL-c (P for linear trend <0.001) were found in the multivariate-adjusted 
regression analysis. WC, SBP, and HOMA-IR were significantly higher and HDL-c was 
significantly lower in the lowest serum vitamin D tertile category compared with the 
highest serum vitamin D tertile category (P < 0.0167). The adjusted mean HOMA-IR of 
subjects was significantly higher in the lowest serum vitamin D tertile category (OR 2.59; 
95% CI: 2.44, 2.75)
 
as compared with the highest serum vitamin D tertile category (OR 
2.25; 95% CI: 2.12, 2.39). There was no association between serum vitamin D and 
fasting plasma glucose (P = 0.38), serum triglyceride (P = 0.55), DBP (P = 0.60), and 
CRP (P for linear trend = 0.18). Also, no association was found between serum vitamin 
D concentration and CRP in children with BMI ≥85th percentile (P = 0.24) (data not 
shown). Detailed associations between serum vitamin D concentrations and individual 
components of MetS are reported in Appendix F. 
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Table 4: Sample sizes for serum vitamin D concentrations by age, sex, race-
ethnicity, PIR, BMI, use of supplements, and time-period of examination in 12-17 y 
children and adolescents in the National Health and Nutrition Examination Surveys 
(NHANESs) 2001-2006
1 
Characteristic Serum vitamin D status P-value 
2
 
 
Tertile 1 
(<19.5 ng/mL) 
(n = 1748) 
Tertile 2 
(19.5-26.2 
ng/mL) 
(n = 1133) 
Tertile 3 
(≥26.2 ng/mL) 
(n = 819) 
 
Sex  
   Boys (n =1820) 
   Girls (n =1880) 
 
773 (42.5) 
 975 (51.9) 
 
588 (32.3) 
545 (29.0) 
 
459 (25.2) 
360 (19.1) 
<0.001 
Race-ethnicity  
   Non-Hispanic white (n =985) 
   Non-Hispanic black (n =1226) 
   Hispanic/Mexican (n =1333)  
   Other (n =156) 
 
141 (14.3) 
902 (73.6) 
624 (46.8) 
     81 (51.9) 
 
353 (38.5) 
239 (19.5) 
492 (36.9) 
49 (31.4) 
 
491(49.8) 
85 (6.9) 
217 (16.3) 
26 (16.7) 
<0.001 
Age  
   12-14 y (n =1859) 
   15-17 y (n =1841) 
 
869 (46.7) 
879 (47.7) 
 
589 (31.7) 
544 (29.5) 
 
401 (21.6) 
418 (22.7) 
0.99 
Poverty income ratio 
3
 
   <1.0  (n =989) 
   1.0-2.5 (n =1259) 
 
566 (57.2) 
641 (50.9) 
 
291 (29.4) 
366 (29.1) 
 
132 (13.3) 
252 (20.0) 
<0.001 
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   ≥2.5  (n =1280) 452 (35.3) 433 (33.8) 395 (30.9) 
Time of examination 
4
 
   Summer (n =1749) 
   Winter (n =1951) 
 
  654 (37.4) 
1094 (56.1) 
 
556 (31.8) 
577 (29.6) 
 
539 (30.8) 
280 (14.4) 
<0.001 
Use of supplements 
3, 5
 
   Yes (n =714) 
   No  (n =2984) 
 
247 (34.6) 
1499 (50.2) 
 
255 (35.7) 
878 (29.4) 
 
212 (29.7) 
607 (20.3) 
<0.001 
Body mass index 
3
 
   <85
th
 percentile (n =3181) 
   ≥85th percentile (n =491) 
 
1408 (44.2) 
319 (65.0) 
 
1011 (31.8) 
118 (24.0) 
 
762 (24.0) 
54 (11.0) 
<0.001 
1
n = 3700, weighted n = 17681659. NHANES 2001-2002, 2003-2004, and 2005-2006 
were combined into one master database, NHANESs 2001-2006. Sample sized based on 
actual cases. Percentages are given in parentheses.  
2
Significance for Rao-Scott χ2 test. 
3
Sample sizes are slightly lower due to missing responses. 
4
Examination was performed during summer (May 1 - October 31) and during winter 
(November 1 - April 30). 
5
Participants who took supplements 1mo before the survey was conducted. 
  
 
 
 
 
Table  5: Multivariate-adjusted odds ratio (OR) and 95 % confidence interval (CI) for metabolic syndrome according 
to tertiles of  serum vitamin D concentrations in 12-17 y old children and adolescents in the National Health and 
Nutrition Examination Surveys (NHANESs) 2001-2006
1 
Variable  Serum vitamin D status
 
P for 
trend
2
 
 Tertile 1 
(<19.5 ng/mL) 
Tertile 2  
(19.5-26.2 
ng/mL) 
Tertile 3 
(≥26.2 ng/mL) 
 
All subjects       
Positive for metabolic syndrome
 
n (%)  
Multivariate-adjusted OR (95% CI) 
3
 
Subjects with body mass index ≥85th 
percentile  
Positive for metabolic syndrome n (%) 
5 
Multivariate-adjusted OR (95% CI) 
6
 
131 (8.7) 
2.26 (1.11, 4.61) 
 
118 (42.0) 
2.05 (0.77, 5.49) 
56 (6.4) 
2.15 (1.14, 4.05) 
 
37(38.6) 
1.5 (0.57, 3.97) 
26 (3.5) 
1.0 
4 
 
17 (32.9) 
1.0
4
 
0.04 
 
 
0.33 
1
n = 3444, weighted n = 16630443. NHANES 2001-2002, 2003-2004, and 2005-2006 were combined into one master 
database, NHANESs 2001-2006. Metabolic syndrome was defined according to the modified National Cholesterol Education 
 
 
 
 
Program- Adult Treatment Panel III criteria, the presence of at least 3 of the criteria: waist circumference >90
th
 percentile for 
age and sex, triglycerides >110 mg/dL (1.24 mmol/l), HDL < 40 mg/dL (1.03 mmol/l), either systolic or diastolic blood 
pressure  >90
th
 percentile for age, sex and height/use of blood pressure medication, and fasting glucose >100 mg/dL (5.55 
mmol/l)/current diabetes diagnosis/ current use of insulin or oral hypoglycemic drugs.  
2
Significance for the effect of metabolic syndrome variable in the multivariate logistic regression analysis. 
3
Logistic regression was adjusted for age, sex, race-ethnicity, and BMI. There was interaction between race-ethnicity and BMI 
(P = 0.02). Poverty income ratio, time of examination, use of supplements, smoking status, and alcohol consumption were 
dropped because these variable were not significant in the model. 
4
Referent category. 
5
n = 491. Subjects with BMI ≥85th percentile. 
6
Logistic regression was adjusted for age, sex, and race-ethnicity. Poverty income ratio, time of examination, use of 
supplements, smoking status, and alcohol consumption were dropped because these variables were not significant in the 
model. 
  
 
 
 
 
Table 6: Adjusted concentrations of indicators of metabolic syndrome according to tertiles of serum vitamin D in 12-17 
y old children and adolescents in the National Health and Nutrition Examination Surveys (NHANESs) 2001-2006
1 
Variable Serum vitamin D status
2 
P-value
3
 
 Tertile 1 
(<19.5 ng/mL) 
Tertile 2  
(19.5-26.2 ng/mL) 
Tertile 3 
(≥26.2 ng/mL) 
 
Waist circumference (cm)
4
 84.4 (83.1,  87,8)
 a
 79.8 (79.0, 80,6) 
b
 76.3 (75.4, 77.2) 
c
 <0.001 
Fasting glucose (mg/dL)
5
 93.7 (91.8, 95.6)
 
 93.7 (91.8, 95.6)
 
 91.8 (90.0, 93.7)
 
 0.38 
HDL-cholesterol (mg/dL)
6
 48.9 (48.4, 49.9)
 a
 48.9 (48.4, 49.9)
 a
 51.9 (50.9, 53.0) 
b 
 <0.001 
Triglyceride (mg/dL)
7
 76.7 (72.2, 81.5)
 
 79.8 (54.1, 83.9)
 
 77.5 (73.0,  82.3)
 
 0.55 
Blood pressure  
Systolic (mm Hg)
8
 
Diastolic (mm Hg)
9
 
 
109.5 (108.5, 110.6)
 a
 
59.6 (58.7, 60.5)
 
 
 
108.3 (107.5,  109.0)
 a, b 
59.9 (58.8, 61.0)
 
 
 
107.6 (106.8, 108.3) 
b 
60.2 (59.1, 61.2)
 
 
 
0.009 
0.60 
C-reactive protein (µg/dL)
10
 43 (96, 48)
 
 48 (44, 52)
 
 49 (48, 50)
 
 0.18 
HOMA-Insulin Resistance 
11
 2.59 (2.44, 2.75)
 a
 2.39 (2.25, 2.53)
 a, b
 2.25 (2.12, 2.39)
 b
 0.003 
1
n = 3444, weighted n = 16630443. NHANES 2001-2002, 2003-2004, and 2005-2006 were combined into one master 
database, NHANESs 2001-2006. 
 
 
 
 
2
Means and 95% confidence intervals. Multiple comparisons were made with Bonferroni correction after testing the hypothesis 
with unpaired, 2-tailed t-test. Means with different superscript letters are significantly different from each other within the row, 
P < 0.0167. 
3
Significance of metabolic syndrome indicator variable in the multivariate regression analysis. 
4
Adjusted for age, sex, race-ethnicity, time of examination, and use of supplements.  
5
Adjusted for age, sex, race-ethnicity, BMI, and time of examination. Analysis was performed on natural log transformed 
values.  
6
Adjusted for age, sex, race-ethnicity, BMI, and PIR. Analysis was performed using on log transformed values. Significance 
for the interaction between sex and race-ethnicity was P < 0.001. 
7
Adjusted for race-ethnicity, BMI, and time of examination. Analysis was performed on natural log transformed values. 
Significance for the interaction between race-ethnicity and BMI was P < 0.001. 
8
Adjusted for age, sex, race-ethnicity, and BMI. Significance for the interaction between gender and race-ethnicity was P < 
0.001. 
9
Adjusted for age and sex. 
10
Adjusted for age, race-ethnicity, BMI, and PIR. Analysis was performed on natural log transformed values. 
11
Adjusted for race-ethnicity, BMI, and use of supplements. Analysis was performed on natural log transformed values. 
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CHAPTER V 
DISCUSSION AND CONCLUSION 
To date, this is the most comprehensive study that investigated the association 
between serum vitamin D and MetS, components of MetS, CRP, and IR in children and 
adolescents in a nationally representative sample survey. We found the prevalence of 
MetS was 6.1% (7.0% boys, 4.3% girls). Previous studies using the modified NCEP-ATP 
III criteria for children found that the prevalence of MetS was between 4.2-12.7% 
18, 21-23, 
39
. We report the prevalence of vitamin D deficiency (<20 ng/mL) in children was 30.5%, 
where as others reported 22-55% using the same serum vitamin D cut-off concentrations 
13, 44, 73
. Other reasons for differences in prevalence of vitamin D deficiency across studies 
are likely due to variability in defining vitamin D status and vitamin D assays 
16
, in 
characteristics of the subjects, geographical location 
43, 51
, season in which serum vitamin 
D measurement was collected, and in the measurement of dietary and supplemental 
vitamin D intakes. 
16, 31
 
In this study, vitamin D deficiency was significantly higher in non-Hispanic black 
(73.6%) as compared with other race-ethnicities 
14, 43, 44
 likely due to differences in skin 
pigmentation. Our findings also agree with previous findings by several investigators. 
31, 
43, 51
 The variability in vitamin D concentration in race-ethnicity is because non-Hispanic 
black need 5-10 times longer sun exposure as compared non-Hispanic white to produce 
45 
 
 
 
the same amount of vitamin D.
52
  Melanin in darker skin is known to interfere with UV 
light production, leading to diminished synthesis of vitamin D.
1
 
In this large population-based study, we confirm the relationship between MetS 
and vitamin D status. The likelihood of having MetS in the highest tertile of serum 
vitamin D concentration was significantly higher relative to the lowest tertile of serum 
vitamin D concentration independent of age, sex, race-ethnicity, and BMI. These findings 
support the findings by several investigators. 
14, 18, 19, 28, 30, 76
 Additionally, serum vitamin 
D was significantly, inversely associated with several components of the MetS such as 
WC, SBP, and HOMA-IR score, and directly associated with low HDL-c in the 
multivariate regression analysis after adjusting the data for several confounding factors. 
In general, our results are in agreement with findings reported by Ford et al 
19
, Reis et al 
76
, and Kumar et al.
14
 Ford et al 
19
 reported an inverse association between vitamin D and 
abdominal obesity, hyperglycemia, and hypertriglyceridemia in NHANES III. Reis et al 
76
 found a significant inverse association between serum vitamin D and MetS 
independent of BMI, parathyroid hormone concentration, and total calcium intake in 
adults (≥20 y) in NHANES 2003-2004. Using the NHANES 2001-2004 data, Kumar et al 
14
 found that serum vitamin D deficiency (<15 ng/mL) was significantly inversely 
associated with elevated BP, and directly associated with HDL-c in 1-21y old children. 
Reis et al 
18
 found low serum vitamin D was significantly associated with MetS and 
components of the MetS such as elevated BP and fasting glucose independent of 
adiposity in 3577 adolescents in NHANES 2001-2004. 
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We found low serum vitamin D significantly associated with increased WC, one 
of the measures of central adiposity. An inverse association between low serum vitamin 
D concentrations and body weight or BMI 
11, 74
 and obesity 
31, 32, 43, 73
 is documented in 
several epidemiological studies. The exact reasons for low serum vitamin D in 
overweight and obese individuals is not clear, but several mechanisms have been 
proposed. First, adiposity might influence the skin‟s capacity to produce vitamin D. 
However, there were no significant differences in the amount of vitamin D precursors 
between obese and non-obese people.
74
 Wortsman et al 
74
 reported a 57% less increase in 
serum vitamin D concentrations in obese compared to non-obese individuals after 24 hr 
sunlight exposure. Hence, the release of vitamin D from skin into circulation may be 
affected in persons with obesity, but the capacity of the skin to produce vitamin D3 is not 
affected in the obese state 
74
. Second, sequestering of the fat soluble vitamin D within the 
adipose tissue has been hypothesized for low vitamin D concentrations in obesity.
74
 Low 
vitamin D concentrations in obese individuals may cause secondary hyperparathyroidism 
leading to an increased influx of intracellular calcium, which in turn may lead to 
increased lipogenesis.
103
 In addition, overweight and obese children are spending longer 
time indoors due to limited mobility and sedentary lifestyle and habits. This lesser sun 
exposure may explain low vitamin D synthesis and circulating concentrations. Thus, poor 
vitamin D status in obese individuals may accentuate obesity.  
Our study is the first to investigate the association between vitamin D and IR on 
US children using the data reported in the recent NHANES 2001-2006. In our study, 
47 
 
 
 
children in the lowest vitamin D tertile had significantly increased IR compared with 
those in the highest vitamin D tertile. Although the mechanism and role of vitamin D in 
IR is not clearly elucidated, it is thought that vitamin D and vitamin-D calcium binding 
protein alter insulin action either at the adipocyte level or affect the release of insulin 
from the pancreatic β-cell, thereby mediating insulin sensitivity.20, 27 A few findings in 
adults suggest an inverse association between serum vitamin D and IR and a direct 
association between vitamin D and insulin sensitivity.
20, 28, 30
 In contrast, Reihner et al 
32
 
and Tangorra et al 
73
 did not find an association between serum vitamin D and IR in 
obese children. The lack of association may be due to a small sample size
 
or high 
prevalence of normal concentrations of 1,25(OH)2D in obese subjects. The association 
between vitamin D and IR is further corroborated by the discovery of polymorphisms in 
VDR gene. These have been found to modify insulin secretion leading to IR and 
dysregulation of glucose homeostasis. 
104, 105
 Stunff et al 
89
 identified a single nucleotide 
polymorphism (SNP) on p110 β gene that was significantly linked with elevated fasting 
glucose, insulin, and HOMA-IR index in obese (BMI > 99.6
th
 percentile) children (n 
=580).  Although a relation between serum vitamin D and IR exists, but the biological 
mechanism through which vitamin D influences the pathophysiology associated with 
T2DM remains unclear.   
Another newly recognized role of vitamin D is its ability to regulate BP by 
suppressing renin gene expression 
67, 77
. The RAS regulates BP and blood volume 
homeostasis 
67, 68
. The RAS is upregulated in obesity 
66
 and excessive RAS stimulation 
can lead to hypertension. The fact that adipose tissue is the site for vitamin D storage and 
is capable of producing all components of the RAS may explain the complex relationship 
48 
 
 
 
between vitamin D, adipocyte, and RAS.
78
 A derangement in this complex system may 
potentially be the cause for elevated BP in overweight and obese individuals with low 
serum vitamin D concentrations.
66, 80
 Findings from epidemiological studies shed light on 
the association between serum vitamin D and elevated BP.
7, 14, 18, 73
 As in our study, Judd 
et al 
7
 also found serum vitamin D (<20 ng/mL) associated with SBP in children and 
adolescents in NHANES III.  In the Framingham Offspring longitudinal study, Wang et 
al 
48
 reported vitamin D deficiency (<15 ng/mL) in 28% of individuals and found twice 
the higher CVD risk in vitamin D deficient individuals that had hypertension. Studies 
suggest reducing elevated BP through vitamin D supplementation
7
 and weight loss.
84
 
The anti-inflammatory role of 1,25(OH)2D has been observed by  numerous 
investigators. 
40, 47, 95
 The location of VDRs on inflammatory cells such as the peripheral 
blood mononuclear cells, T-lymphocyte, and macrophages is reason to believe that 
vitamin D also mediates the immune system response and inflammatory process. 
40, 47, 95
 
The mechanism through which vitamin D deficiency affects the inflammatory marker, 
CRP is not clear. 
40, 68
 Sun et al 
40
 confirmed that the expression of various cytokines such 
as as interleukin (IL)-1, IL-6, IL-8, and TNF are down-regulated by 1,25(OH)2D and that 
VDRs are involved in the inflammatory response pathway through its regulation of the 
nuclear factor kappa-light-enhancer of the activated B cells (NF-kB). Evidence suggests 
that CRP is significantly associated with obesity 
33, 34, 39
 and MetS and its components 
33, 
38, 39
 in children. In addition, low-grade inflammation is associated with CVD and 
hypertension as well.
36
 Therefore, we hypothesized there would be an inverse relation 
between serum vitamin D and CRP. However, in this study we found no association 
between serum vitamin D concentrations and CRP in children. Lack of a relation between 
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serum vitamin D and CRP in this study may be due to relatively modest sample size and 
fewer overweight and obese children (BMI ≥85th percentile). Michos et al 15 found a 
weak inverse correlation between CRP and serum vitamin D, but this association was null 
after adjustment was made for BMI in the multivariate model. The use of a small sample 
size (n =650) could have deterred detection of an association.  
This study has several strengths. The use of a nationally representative survey 
with large sample size of children and adolescents (n= 3700) allowed us to examine the 
relationship of vitamin D with MetS after taking into account several confounding 
variables. This study investigated not only the association between vitamin D and MetS, 
but also included the association between vitamin D and IR and inflammation. Previous 
studies that investigated the association between vitamin D and MetS in children had not 
investigated IR and inflammation.
14, 18
 In addition, the use of HOMA-IR method allowed 
for less expensive and less invasive measurement of IR 
89
. Although HOMA-IR is not the 
gold standard for the measurement of IR, it is considered a valid index for measurement 
of IR in epidemiological studies.
89
 
The measurement of cause and effect relation is not possible because of the cross-
sectional design of the study. Lack of uniform guidelines to define vitamin D deficiency 
or insufficiency make interpretation and comparison of results with published results 
challenging. 
43, 106
 The possibility of variability in the vitamin D assay could influence 
results from the combined NHANES data, since the serum samples were collected in 
north (>35 °N) in summer and in south (<35 °N) during winter. This variability is 
unlikely because we adjusted the serum vitamin D data to account for changes in assay 
between NHANES cycles using the NCHS guidelines. Not all potential confounding 
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factors influencing vitamin D concentrations could be taken into account in our analysis, 
because we were limited by a lack of information on geographical location, participant‟s 
use of sunscreen and nature of clothing. While the study looked at the generalized used of 
supplements, it would have been more useful to address only vitamin D supplement 
users.  
In conclusion, children with poor vitamin D status are at increased risk for MetS 
and IR. Coexistence of poor vitamin D status with several of components of MetS such as 
increased WC, SBP, IR and low HDL-c is a concern because children with MetS are at 
high risk for future CVD. The risk is further accentuated with concomitant presence of 
vitamin D deficiency. Studies are warranted to define appropriate cuts off values for 
concentrations of vitamin D deficiency or insufficiency. Because of negative health 
outcomes associated with MetS and poor vitamin D status when existed individually or in 
combination, early detection and intervention of these conditions are paramount in 
children. Interventions to improve the vitamin D status of children should be targeted at 
improving the availability of vitamin D fortified foods in school nutrition programs and 
at the Women Infants and Children program
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APPENDICES  
 
APPENDIX A 
 
SAMPLE SIZE AND HEALTH CHARACTERISCTICS OF 12-17 y 
OLD CHILDREN AND ADOLESCENTS IN NHANES 2001-2006 
                                  S U D A A N                                                          
            Software for the Statistical Analysis of Correlated Data                                   
          Copyright      Research Triangle Institute      October 2009                                 
                                Release 10.0.1                                                         
DESIGN SUMMARY: Variances will be computed using the Taylor Linearization Method, 
Assuming a With      
Replacement (WR) Design                                                                                
    Sample Weight: MEC6YR                                                                              
    Stratification Variables(s): SDMVSTRA                                                              
    Primary Sampling Unit: SDMVPSU                                                                     
Number of observations read    :  30070    Weighted count :285937478                                   
Observations in subpopulation  :   3700    Weighted count : 17681659                                   
Denominator degrees of freedom :     45                                                                
Variance Estimation Method: Taylor Series (WR)                                                         
For Subpopulation: METSYNPREV = 1  by: Variable, SUDAAN Reserved Variable One.                                                            
---------------------------------------------------- 
Variable 
   Gender                 size       mean         SE 
----------------------------------------------------- 
Waist Circumference  (cm) 
   Total                   3648     78.414     0.3737 
   1                       1799     78.631     0.4355 
   2                       1849     78.204     0.5057 
 
Variable 
   SUDAAN Reserved                                      Geometric 
     Variable One          size       mean         SE   mean          SE 
--------------------------------------------------------------------------- 
Age at Screening 
  Adjudicated - 
  Recode 
   Total                   3700     14.499     0.0454   14.397     0.0452 
   1                       3700     14.499     0.0454   14.397     0.0452 
average diastolic 1 
  reading (mm/Hg) 
   Total                   3652     59.013     0.3498   58.230     0.3275 
   1                       3652     59.013     0.3498   58.230     0.3275 
average systolic 1 
  reading (mm/Hg) 
   Total                   3652    107.112     0.2766  106.668     0.2809 
   1                       3652    107.112     0.2766  106.668     0.2809 
Waist Circumference 
  (cm) 
   Total                   3648     78.414     0.3737  77.470     0.3515
67 
 
 
 
 
   1                       3648     78.414     0.3737  77.470     0.3515 
Body Mass Index 
  (kg/m**2) 
   Total                   3672     22.339     0.1411  21.859     0.1284 
   1                       3672     22.339     0.1411  21.859     0.1284 
VITD 
   Total                   3700     23.936     0.3936  22.208     0.3870 
     1                       3700     23.936     0.3936  22.208     0.3870 
Direct HDL- 
  Cholesterol 
  (mg/dL) 
   Total                   3692     52.699     0.2865  51.417     0.2773 
   1                       3692     52.699     0.2865  51.417     0.2773 
Triglyceride (mg/dL) 
   Total                   2203     88.869     2.4247  77.828     1.3717 
   1                       2203     88.869     2.4247  77.828     1.3717 
GLUCOSE 
   Total                   2216     93.865     0.5328  92.993     0.3578 
   1                       2216     93.865     0.5328  92.993     0.3578 
INSULIN 
   Total                   2201     13.129     0.4185  10.511     0.2453 
   1                       2201     13.129     0.4185  10.511     0.2453 
HOMAIR 
   Total                   2198      3.145     0.1247  2.415     0.0587 
   1                       2198      3.145     0.1247  2.415     0.0587 
C-reactive 
  protein(mg/dL) 
   Total                   3700      0.146     0.0108  0.043     0.0012 
   1                       3700      0.146     0.0108  0.043     0.0012 
--------------------------------------------------------------------------- 
The FREQ Procedure 
                    Cumulative 
age    Frequency     Frequency 
  1        1859          1859 
  2        1841          3700 
               Gender 
                          Cumulative 
RIAGENDR    Frequency     Frequency 
       1        1820          1820 
       2        1880          3700 
                     Cumulative 
race    Frequency     Frequency 
   1         985           985 
   2        1226          2211 
   3        1333          3544 
   4         156          3700 
                    Cumulative 
pir    Frequency     Frequency 
  1         989           989 
  2        1259          2248 
  3        1280          3528 
  4         172          3700 
        
Six month time period 
                         Cumulative 
RIDEXMON    Frequency     Frequency
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       1        1951          1951 
       2        1749          3700 
 
  Any dietary supplements taken? 
                       Cumulative 
DSD010    Frequency     Frequency 
     1         714           714 
     2        2984          3698 
     3           2          3700 
 
                         Cumulative 
bmigroup    Frequency     Frequency 
       1        3181          3181 
       2         491          3672 
       3          28          3700 
Variable 
   SUDAAN Reserved     Sample 
     Variable One      size          Percent 
-------------------------------------------- 
AGE: 1 
   Total                   3700        50.18 
   1                       3700        50.18 
Gender: 1 
   Total                   3700        49.14 
   1                       3700        49.14 
RACE: 1 
   Total                 3700        61.77 
   1                       3700        61.77 
PIR: 1 
   Total                 3700        17.40 
   1                       3700        17.40 
Six month time 
  period:  
   Total                 3700        41.14 
   1                       3700        41.14 
Any dietary 
  supplements 
  taken?: 1 
   Total                 3700        24.13 
   1                       3700        24.13 
BMIGROUP: 1 
   Total                   3700        87.89 
   1                       3700        87.89 
AGE: 2 
   Total                   3700        49.82 
   1                       3700        49.82 
Gender: 2 
   Total                   3700        50.86 
   1                       3700        50.86 
RACE: 2 
   Total                   3700        14.57 
   1                       3700        14.57 
PIR: 2 
   Total                   3700        28.79 
   1                       3700        28.79 
Six month time 
  period: 2 
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   Total                   3700        58.86 
   1                       3700        58.86 
Any dietary  supplements  taken?: 2 
   Total                   3700        75.81 
   1                       3700        75.81 
BMIGROUP: 2 
   Total                   3700        11.47 
   1                       3700        11.47 
--------------------------------------------------------------- 
|                |                  | SUDAAN Reserved         | 
| Variable        |                  | Variable One            | 
|                 |                  |-------------------------| 
|                 |                  | Total      | 1          | 
---------------------------------------------------------------- 
| RACE: 3         | Sample size      |       3700 |       3700 | 
|                 | Percent          |      17.60 |      17.60 | 
| PIR: 3          | Sample size      |       3700 |       3700 | 
|                 | Percent          |      49.98 |      49.98 | 
|                 |                  |            |            | 
| Any dietary     | Sample size      |       3700 |       3700 | 
| supplements     | Percent          |       0.06 |       0.06 | 
| taken?: 3       |                  |            |            | 
| BMIGROUP: 3     | Sample size      |       3700 |       3700 | 
|                 | Percent          |       0.64 |       0.64 | 
| RACE: 4         | Sample size      |       3700 |       3700 | 
|                 | Percent          |       6.07 |       6.07 | 
| PIR: 4          | Sample size      |       3700 |       3700 | 
|                 | Percent          |       3.84 |       3.84 | 
---------------------------------------------------------------- 
The FREQ Procedure                                                                               
                                Cumulative    Cumulative                                                
VD    Frequency     Percent     Frequency      Percent                                                                         
 1        1748       47.24          1748        47.24                                                  
 2        1541       41.65          3289        88.89                                                  
 3         411       11.11          3700       100.00                                                  
  --------------------------------------------                                                           
    Variable One      size          Percent                                                           
--------------------------------------------                                                           
VSTATUS2: 1                                                                                            
   Total                   3700        30.57                                                           
   1                       3700        30.57                                                           
VD: 1                                                                                                  
   Total                   3700        30.57                                                           
   1                       3700        30.57                                                           
VSTATUS2: 2                                                                                            
   Total                   3700        34.20                                                           
   1                       3700        34.20                                                           
VD: 2                                                                                                  
   Total                   3700        49.77                                                           
   1                       3700        49.77                                                               
VSTATUS2: 3                                                                                            
   Total                   3700        35.23                                                           
   1                       3700        35.23                                                           
VD: 3                                                                                                  
   Total                   3700        19.66                                                           
   1                       3700        19.66                                                   
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APPENDIX B 
 
CHARACTERISTICS OF 12-17y  OLD CHILDREN AND 
ADOLESCENTS WITH METABOLIC SYNDROME IN NHANES 
2001-2006 
 
The FREQ Procedure 
                       Cumulative 
metsyn    Frequency     Frequency 
     0        3487          3487 
     1         213          3700 
 
Table of age by metsyn 
      age       metsyn 
 
Frequency‚       0‚       1‚  Total 
       1 ‚   1753 ‚    106 ‚   1859 
       2 ‚   1734 ‚    107 ‚   1841 
Total        3487      213     3700 
 
Table of RIAGENDR by metsyn 
RIAGENDR(Gender)     metsyn 
Frequency‚       0‚       1‚  Total 
       1 ‚   1693 ‚    127 ‚   1820 
       2 ‚   1794 ‚     86 ‚   1880 
Total        3487      213     3700 
 
Table of race by metsyn 
    Race   metsyn 
Frequency‚       0‚       1‚  Total 
       1 ‚    920 ‚     65 ‚    985 
       2 ‚   1177 ‚     49 ‚   1226 
       3 ‚   1241 ‚     92 ‚   1333 
       4 ‚    149 ‚      7 ‚    156 
Total        3487      213     3700 
 
Table of pir by metsyn 
pir       metsyn 
Frequency‚       0‚       1‚  Total 
       1 ‚    933 ‚     56 ‚    989 
       2 ‚   1185 ‚     74 ‚   1259 
       3 ‚   1208 ‚     72 ‚   1280 
       4 ‚    161 ‚     11 ‚    172 
Total        3487      213     3700 
 
Table of RIDEXMON by metsyn 
RIDEXMON(Six month time period) 
          metsyn 
Frequency‚       0‚       1‚  Total 
       1 ‚   1829 ‚    122 ‚   1951 
       2 ‚   1658 ‚     91 ‚   1749 
Total        3487      213     3700 
 
Table of DSD010 by metsyn 
DSD010(Any dietary supplements taken?) 
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          metsyn 
Frequency‚       0‚       1‚  Total 
       1 ‚    685 ‚     29 ‚    714 
       2 ‚   2801 ‚    183 ‚   2984 
       3 ‚      1 ‚      1 ‚      2 
Total        3487      213     3700 
 
Table of bmigroup by metsyn 
bmigroup     metsyn 
Frequency‚       0‚       1‚  Total 
       1 ‚   3140 ‚     41 ‚   3181 
       2 ‚    319 ‚    172 ‚    491 
       3 ‚     28 ‚      0 ‚     28 
Total        3487      213     3700 
 
Table of vstatus2 by metsyn 
vstatus2     metsyn 
Frequency‚       0‚       1‚  Total 
       1 ‚   1617 ‚    131 ‚   1748 
       2 ‚   1077 ‚     56 ‚   1133 
       3 ‚    793 ‚     26 ‚    819 
Total        3487      213     3700 
 
Table of vstatus2 by metsyn 
vstatus2     metsyn 
Frequency‚       0‚       1‚  Total 
       1 ‚    201 ‚    118 ‚    319 
       2 ‚     81 ‚     37 ‚    118 
       3 ‚     37 ‚     17 ‚     54 
Total         319      172      491 
|                 |                  | AGE                                  | 
| Variable        |                  |-------------------------------------| 
|                 |                  | Total      | 1          | 2          | 
|   TSYN: 1       | Sample size      |       3700 |       1859 |       1841 | 
|                 | Percent          |       6.07 |       5.90 |       6.25 | 
|                 |                  | Gender                               |      
METSYN: 1       | Sample size      |       3700 |       1820 |       1880 | 
|                 | Percent          |       6.07 |       7.91 |       4.29 | 
|                 |                  | RACE                                                            
|                 |                  | Total      | 1          | 2          | 3     | 4           
| METSYN: 1       | Sample size      |  3700 |        985 |       1226 |       1333 | 156 
||            | Percent          |  6.07 |       6.58 |       4.24 |       6.62 |3.73  
|                 |                  | PIR                                                             
|                 | Total            | 1          | 2          | 3          | 4          
|| METSYN: 1       | Sample size      | 3700 |     989 |       1259 |       1280 |    172 
||                 | Percent          | 6.07 |     6.54 |       6.39 |      5.57 |  8.01 
||                 |                  | Six month time period                | 
| |                 |                | Total      | 1          | 2          | 
| METSYN: 1       | Sample size      |       3700 |       1951 |       1749 | 
|                 | Percent          |       6.07 |       5.19 |       6.68 | 
|                 |                  | Any dietary supplements taken?                    
|| METSYN: 1       | Sample size      |       3700 |        714 |       2984 |          2 
||                 | Percent          |       6.07 |       4.18 |       6.61 |      81.92 
| 
|                 |                  | BMIGROUP                                          
| 
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|                 |                  | Total      | 1          | 2          | 3          
|| METSYN: 1       | Sample size      |       3700 |       3181 |        491 |         28 
||                 | Percent          |       6.07 |       1.81 |      39.07 |       0.00 
||                 |                  | VSTATUS2                                          
| METSYN: 1       | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |       6.07 |       8.71 |       6.36 |       3.50 
|| METSYN: 1       | Sample size      |        491 |        319 |        118 |         54 
|| BMI ≥85th percentile | Percent      |      39.07 |      41.96 |      38.58 |      32.85 
|---------------------------------------------------------------------------------------- 
DIFFERENCE IN PREVALENCE OF METS USING RAO-SCOTT CHI-
SQUARE TEST 
                                  Table of RIAGENDR by metsyn                                    
                                                                  Row     Column                 
               RIAGENDR    metsyn     Frequency    Percent    Percent    Percent               
                   Male        No          1693    45.2568    92.0919    48.1814                 
                              Yes           127     3.8863     7.9081    64.0239                 
                            Total          1820    49.1430    100.000                            
                 Female        No          1794    48.6732    95.7061    51.8186                 
                              Yes            86     2.1838     4.2939    35.9761                 
                            Total          1880    50.8570    100.000                            
                  Total        No          3487    93.9299               100.000                 
                              Yes           213     6.0701               100.000                 
                            Total          3700    100.000                                       
                               Rao-Scott Modified Chi-Square Test                                
                                 Pearson Chi-Square    21.1853                                   
                                 Design Correction      1.2883                                   
                                 Rao-Scott Chi-Square  16.4442                                   
                                 DF                          1                                   
                                 Pr > ChiSq             <.0001                                   
                                 F Value               16.4442                                   
                                 Num DF                      1                                   
                                 Den DF                     45                                   
                                 Pr > F                 0.0002                                   
                                                                                                 
                                    Table of race by metsyn                                      
                                                                          Row     Column         
                           race    metsyn     Frequency    Percent    Percent    Percent         
       ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ         
             Non-hispanic white        No           920    57.7061    93.4244    61.4353         
                                      Yes            65     4.0616     6.5756    66.9123         
                                    Total           985    61.7677    100.000                    
             Non-hispanic black        No          1177    13.9476    95.7597    14.8489         
                                      Yes            49     0.6176     4.2403    10.1746         
                                    Total          1226    14.5652    100.000                   
       Hispnic/Mexican American        No          1241    16.4357    93.3826    17.4979         
                                      Yes            92     1.1647     6.6174    19.1875         
                                    Total          1333    17.6004    100.000                    
                          Other        No           149     5.8405    96.2722     6.2179         
                                      Yes             7     0.2262     3.7278     3.7257         
                                    Total           156     6.0666    100.000                    
                          Total        No          3487    93.9299               100.000         
                                      Yes           213     6.0701               100.000         
                                    Total          3700    100.000                               
 
                                    Table of race by metsyn                                      
                               Rao-Scott Modified Chi-Square Test                                
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                                  Pearson Chi-Square    6.6912                                   
                                  Design Correction     1.1393                                   
                                  Rao-Scott Chi-Square  5.8733                                   
                                  DF                         3                                   
                                  Pr > ChiSq            0.1179                                   
                                  F Value               1.9578                                   
                                  Num DF                     3                                   
                                  Den DF                   135                                   
                                  Pr > F                0.1233                                   
                                     Table of age by metsyn                                      
                                                                 Row     Column                  
                   age    metsyn     Frequency    Percent    Percent    Percent                  
                ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ                  
                12-14y        No          1753    47.2201    94.1043    50.2716                  
                             Yes           106     2.9583     5.8957    48.7366                  
                                                                                                 
                           Total          1859    50.1784    100.000                             
                ---------------------------------------------------------------                  
                15-17y        No          1734    46.7099    93.7543    49.7284                  
                             Yes           107     3.1117     6.2457    51.2634                  
                                                                                                 
                           Total          1841    49.8216    100.000                             
                ---------------------------------------------------------------                  
                 Total        No          3487    93.9299               100.000                  
                             Yes           213     6.0701               100.000                  
                                                                                                 
                           Total          3700    100.000                                        
                               Rao-Scott Modified Chi-Square Test                                
                                  Pearson Chi-Square    0.1988                                   
                                  Design Correction     1.9271                                   
                                  Rao-Scott Chi-Square  0.1032                                   
                                  DF                         1                                   
                                  Pr > ChiSq            0.7481                                   
                                  F Value               0.1032                                   
                                  Num DF                     1                                   
                                  Den DF                    45                                   
                                  Pr > F                0.7495                                   
Table of age by metsyn                                      
                                                                 Row     Column                  
                   age    metsyn     Frequency    Percent    Percent    Percent                  
                ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ                  
                12-14y        No          1753    47.2201    94.1043    50.2716                  
                             Yes           106     2.9583     5.8957    48.7366                  
                                                                                                 
                           Total          1859    50.1784    100.000                             
                ---------------------------------------------------------------                  
                15-17y        No          1734    46.7099    93.7543    49.7284                  
                             Yes           107     3.1117     6.2457    51.2634                  
                                                                                                 
                           Total          1841    49.8216    100.000                             
                ---------------------------------------------------------------                  
                 Total        No          3487    93.9299               100.000                  
                             Yes           213     6.0701               100.000                  
                                                                                                 
                           Total          3700    100.000                                        
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                               Rao-Scott Modified Chi-Square Test                                
                                                                                                 
                                  Pearson Chi-Square    0.1988                                   
                                  Design Correction     1.9271                                   
                                                                                                 
                                  Rao-Scott Chi-Square  0.1032                                   
                                  DF                         1                                   
                                  Pr > ChiSq            0.7481                                   
                                                                                                 
                                  F Value               0.1032                                   
                                  Num DF                     1                                   
                                  Den DF                    45                                   
                                  Pr > F                0.7495                                   
 
 Table of age by metsyn                                      
                                                                                                 
                                                                 Row     Column                  
                   age    metsyn     Frequency    Percent    Percent    Percent                  
                ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ                  
                12-14y        No          1753    47.2201    94.1043    50.2716                  
                             Yes           106     2.9583     5.8957    48.7366                  
                                                                                                 
                           Total          1859    50.1784    100.000                             
                ---------------------------------------------------------------                  
                15-17y        No          1734    46.7099    93.7543    49.7284                  
                             Yes           107     3.1117     6.2457    51.2634                  
                                                                                                 
                           Total          1841    49.8216    100.000                             
                ---------------------------------------------------------------                  
                 Total        No          3487    93.9299               100.000                  
                             Yes           213     6.0701               100.000                  
                                                                                                 
                           Total          3700    100.000                                        
                ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ                  
                              
         Rao-Scott Modified Chi-Square Test                                
                                  Pearson Chi-Square    0.1988                                   
                                  Design Correction     1.9271                                   
                                                                                                 
                                  Rao-Scott Chi-Square  0.1032                                   
                                  DF                         1                                   
                                  Pr > ChiSq            0.7481                                   
                                                                                                 
                                  F Value               0.1032                                   
                                  Num DF                     1                                   
                                  Den DF                    45                                   
                                  Pr > F                0.7495                                   
                                                                                                 
     Table of pir by metsyn                                      
                                                                                                 
                                                                          Row     Column         
                            pir    metsyn     Frequency    Percent    Percent    Percent         
       ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ         
               low income: <1.0        No           933    16.9108    93.4610    17.9888         
                                      Yes            56     1.1832     6.5390    19.7436     
                                    Total           989    18.0939    100.000                    
       ---------------------------------------------------------------------------------         
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       moderate income: 1.0-2.5        No          1185    28.0230    93.6068    29.8093         
                                      Yes            74     1.9139     6.3932    31.9382         
                                    Total          1259    29.9369    100.000                    
       ---------------------------------------------------------------------------------         
               high income:=2.5        No          1208    49.0736    94.4284    52.2019         
                                      Yes            72     2.8955     5.5716    48.3182         
Total         1280    51.9692    100.000                    
       ---------------------------------------------------------------------------------         
                          Total        No          3326    94.0074               100.000         
                                      Yes           202     5.9926               100.000         
                                Total         3528    100.000                               
       ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ         
                                    Frequency Missing = 172                                      
                                          
      Table of pir by metsyn                                      
                                                                                                 
                               Rao-Scott Modified Chi-Square Test                                
                                                                                                 
                                  Pearson Chi-Square    1.2160                                   
                                  Design Correction     1.5717                                   
                                                                                                 
                                  Rao-Scott Chi-Square  0.7737                                   
                                  DF                         2                                   
                                  Pr > ChiSq            0.6792                                   
                                                                                                 
                                  F Value               0.3868                                   
                                  Num DF                     2                                   
                                  Den DF                    90                                   
                                  Pr > F                0.6803                                   
                                       Sample Size = 3528                                          
Table of RIDEXMON by metsyn                                    
                                                                                                 
                                                                  Row     Column                 
               RIDEXMON    metsyn     Frequency    Percent    Percent    Percent                 
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ                 
                 winter        No          1829    39.0040    94.8095    41.5246                 
                              Yes           122     2.1353     5.1905    35.1781                 
                                                                                                 
                            Total          1951    41.1393    100.000                            
               -----------------------------------------------------------------                 
                 summer        No          1658    54.9259    93.3152    58.4754                 
                              Yes            91     3.9347     6.6848    64.8219                 
                                                                                                 
                            Total          1749    58.8607    100.000                            
               -----------------------------------------------------------------                 
                  Total        No          3487    93.9299               100.000                 
                              Yes           213     6.0701               100.000                 
                                                                                                 
                            Total          3700    100.000                                       
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ                 
                               Rao-Scott Modified Chi-Square Test                                
                       
                                  Pearson Chi-Square    3.5090                                   
                                  Design Correction     1.9537                                   
                                                                                                 
                                  Rao-Scott Chi-Square  1.7960                                   
                                  DF                         1                                   
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                                  Pr > ChiSq            0.1802                                   
                                                                                                 
                                  F Value               1.7960                                   
                                  Num DF                     1                                   
                                  Den DF                    45                                   
                                  Pr > F                0.1869                                   
Table of bmigroup by metsyn                                    
                                                                                                 
                                                                                 Row     
Column  
                              bmigroup    metsyn     Frequency    Percent    Percent    
Percent  
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
ƒƒƒƒƒƒ  
           Normal wt: <85th percentile        No          3140    86.8576    98.1907    
92.5094  
                                             Yes            41     1.6005     1.8093    
26.1975  
                                                                                                 
                                           Total          3181    88.4581    100.000             
-----------------------------------------------------------------------------------------
------  
Overweight and obese:>=85th percentile        No           319     7.0330    60.9346     
7.4906  
                                             Yes           172     4.5089    39.0654    
73.8025  
                                                                                                 
                                           Total           491    11.5419    100.000             
                                 Total        No          3459    93.8906    100.000  
                                             Yes           213     6.1094    100.000  
                                           Total          3672    100.000                        
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ  
                                     Frequency Missing = 28                                      
                               Rao-Scott Modified Chi-Square Test                                
                                                                                                 
                                 Pearson Chi-Square    907.1730                                  
                                 Design Correction       9.1762                                  
                                                                                                 
                                 Rao-Scott Chi-Square   98.8612                                  
                                 DF                           1                                  
                                 Pr > ChiSq              <.0001                                  
                                                                                                 
                                 F Value                98.8612                                  
                                 Num DF                       1                                  
                                 Den DF                      45                                  
                                 Pr > F                  <.0001                                  
                                       Sample Size = 3672                                        
                                                                                                                                   
Table of VITAMIND by metsyn                               
                                                                     Row     Column              
                  VITAMIND    metsyn     Frequency    Percent    Percent    Percent              
             ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ              
                deficiency        No          1781    32.2832    91.1831    34.3694              
                                 Yes           138     3.1216     8.8169    51.4259              
                                                                                                 
                               Total          1919    35.4048    100.000                         
             insufficiency        No          1309    42.7540    95.1412    45.5169              
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                                 Yes            61     2.1834     4.8588    35.9705              
                               Total          1370    44.9375    100.000                         
               sufficiency        No           397    18.8927    96.1082    20.1136              
                                 Yes            14     0.7650     3.8918    12.6036              
                               Total           411    19.6578    100.000                         
                     Total        No          3487    93.9299               100.000              
                                 Yes           213     6.0701               100.000              
                               Total          3700    100.000                                    
             ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ              
                               Rao-Scott Modified Chi-Square Test                                
                                                                                                 
                                 Pearson Chi-Square    27.6657                                   
                                 Design Correction      1.4262                                   
                                                                                                 
                                 Rao-Scott Chi-Square  19.3982                                   
                                 DF                          2                                   
                                 Pr > ChiSq             <.0001                                   
                                                                                                 
                                 F Value                9.6991                                   
                                 Num DF                      2                                   
                                 Den DF                     90                                   
                                 Pr > F                 0.0002                                   
                                                                                                 
 Table of supp by metsyn                                     
                                                                 Row     Column                  
                  supp    metsyn     Frequency    Percent    Percent    Percent                  
                 ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ                  
                   yes        No           685    23.1343    95.8201    24.6173                  
                             Yes            29     1.0092     4.1799    16.7519                  
                           Total           714    24.1435    100.000                             
                    no        No          2801    70.8414    93.3888    75.3827                  
                             Yes           183     5.0151     6.6112    83.2481                  
                           Total          2984    75.8565    100.000                             
                           Total        No          3486    93.9758               100.000                  
                             Yes           212     6.0242               100.000                  
                           Total          3698    100.000                                        
                 ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ                  
                                      Frequency Missing = 2                                      
                               Rao-Scott Modified Chi-Square Test                                
                                                                                                 
                                  Pearson Chi-Square    7.0719                                   
                                  Design Correction     1.2584                                   
                                                                                                 
                                  Rao-Scott Chi-Square  5.6197                                   
                                  DF                         1                                   
                                  Pr > ChiSq            0.0178                                   
                                                                                                 
                                  F Value               5.6197                                   
                                  Num DF                     1                                   
                                  Den DF                    45                                   
                                  Pr > F                0.0221           
                                       Sample Size = 3698                                      
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APPENDIX C 
 
DESCRIPTIVE STATISTICS FOR PREVALENCE OF VITAMIN D 
DEFICIENCY IN 12-17 y OLD CHLDREN AND ADOLESCENTS IN 
NHANES 2001-2006 
 
The FREQ Procedure 
Table of age by VD 
age       VD 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚    869 ‚    790 ‚    200 ‚   1859 
       2 ‚    879 ‚    751 ‚    211 ‚   1841 
Total        1748     1541      411     3700 
 
Table of RIAGENDR by VD 
RIAGENDR(Gender)     VD 
Frequency‚      1 ‚      2 ‚      3 ‚  Total 
       1 ‚    773 ‚    821 ‚    226 ‚   1820 
       2 ‚    975 ‚    720 ‚    185 ‚   1880 
Total        1748     1541      411     3700 
 
Table of race by VD 
race      VD 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚    141 ‚    550 ‚    294 ‚    985 
       2 ‚    902 ‚    296 ‚     28 ‚   1226 
       3 ‚    624 ‚    628 ‚     81 ‚   1333 
       4 ‚     81 ‚     67 ‚      8 ‚    156 
Total        1748     1541      411     3700 
 
Table of pir by VD 
pir       VD 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚    566 ‚    367 ‚     56 ‚    989 
       2 ‚    641 ‚    498 ‚    120 ‚   1259 
       3 ‚    452 ‚    620 ‚    208 ‚   1280 
       4 ‚     89 ‚     56 ‚     27 ‚    172 
Total        1748     1541      411     3700 
 
Table of RIDEXMON by VD 
RIDEXMON(Six month time period)     VD 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚   1094 ‚    743 ‚    114 ‚   1951 
       2 ‚    654 ‚    798 ‚    297 ‚   1749 
Total        1748     1541      411     3700 
 
Table of DSD010 by VD 
DSD010(Any dietary supplements taken?) 
          VD 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚    247 ‚    360 ‚    107 ‚    714 
       2 ‚   1499 ‚   1181 ‚    304 ‚   2984 
       3 ‚      2 ‚      0 ‚      0 ‚      2 
Total        1748     1541      411     3700 
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Table of bmigroup by VD 
bmigroup     VD 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚   1408 ‚   1391 ‚    382 ‚   3181 
       2 ‚    319 ‚    143 ‚     29 ‚    491 
       3 ‚     21 ‚      7 ‚      0 ‚     28 
Total        1748     1541      411     3700 
|                     VD                                      
| Variable               | Total      | 1          | 2          | 3          | 
| AGE: 1    | Sample size|      3700 |       1748 |       1541 |        411  
|           | Percent    |     50.18 |      50.05 |      50.37 |      49.89  
Gender: 1 | Sample siz |      3700 |       1748 |       1541 |        411  
|           | Percent    |     49.14 |      43.60 |      50.79 |      53.58           
|RACE: 1    | Sample si  |      3700 |       1748 |       1541 |        411 |           
| Percent    |      61.77 |    29.46 |      70.09 |      90.96 | 
|PIR: 1     | Sample size|      3700 |       1748 |       1541 |        411  
|           | Percent    |     17.40 |      25.72 |      15.24 |       9.93  
| Six month time| Sample size|  3700 |       1748 |       1541 |        411 |  
period: 1| Percent    |        41.14 |      57.36 |      38.59 |      22.36  
| Any dietar| Sample size|      3700 |       1748 |       1541 |        411 |  
supplements Percent    |       24.13 |      17.84 |      26.45 |      28.05 |  
taken?: 1        
| BMIGROUP: 1| Sample size|     3700 |       1748 |       1541 |        411 |        
 Percent      |      87.89 |    80.13 |      90.69 |      92.86 | 
- AGE: 2| Sample size  |        3700 |       1748 |       1541 |        411 
|       | Percent      |       49.82 |      49.95 |      49.63 |      50.11 | 
|Gender: 2| Sample size|        3700 |       1748 |       1541 |        411 | 
|         | Percent    |       50.86 |      56.40 |      49.21 |      46.42 | 
| RACE: 2 | Sample size|        3700 |       1748 |       1541 |        411 | 
|         | Percent    |       14.57 |      35.23 |       7.00 |       1.60 | 
| PIR: 2  | Sample size|        3700 |       1748 |       1541 |        411 | 
|         | Percent    |       28.79 |      33.08 |      27.74 |      24.76 | 
| Six month time| Sample size | 3700 |       1748 |       1541 |        411 | 
| period: 2     | Percent     |58.86 |      42.64 |      61.41 |      77.64 | 
| Any dietary   | Sample size | 3700 |       1748 |       1541 |        411 | 
| supplements   | Percent     |75.81 |      81.96 |      73.55 |      71.95 | 
| taken?: 2        
| BMIGROUP: 2   | Sample size | 3700 |       1748 |       1541 |        411 | 
|               | Percent     | 11.47|      18.45 |       8.89 |       7.14  
| RACE: 3       | Sample size   3700 |       1748 |       1541 |        411 | 
|               | Percent      17.60 |      24.69 |      17.81 |       6.04 | 
| PIR: 3        | Sample size   3700 |       1748 |       1541 |        411 | 
|               | Percent      49.98 |      36.83 |      54.76 |      58.31 | 
| Any dietary   | Sample size   3700 |       1748 |       1541 |        411 | 
| supplements   | Percent       0.06 |       0.20 |       0.00 |       0.00 | 
| taken?: 3        
| BMIGROUP: 3   | Sample size   3700 |       1748 |       1541 |        411 | 
|               | Percent       0.64 |       1.42 |       0.42 |       0.00 | 
| RACE: 4       | Sample size   3700 |       1748 |       1541 |        411 | 
|               | Percent       6.07 |      10.63 |       5.11 |       1.40 | 
----------------------------------------------------------------------------- 
| PIR: 4        | Sample size   3700 |       1748 |       1541 |        411 | 
|               | Percent       3.84 |       4.37 |       2.26 |       6.99 | 
 
DIFFERENCE IN PREVALENCE OF VITAMIN D USING RAO-SCOTT 
CHI-SQUARE TEST                                                
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                                         Data Summary                                          
                                                                          
                              Number of Strata                  45                               
                              Number of Clusters                90                               
                              Number of Observations          3700                               
                              Sum of Weights              17681659                               
                                   Table of RIAGENDR by vtert                                   
                                                                        Row     Column       
     RIAGENDR                         vtert     Frequency    Percent    Percent    
Percent       
     
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ       
         Male        Tertile 1: <19.5 ng/mL           773    13.3312    27.1273    3.6035       
                 Tertile 2: 19.5-26.2 ng/mL           588    16.7110    34.0048   48.8686       
                     Tertile 3: >26.2 ng/mL           459    19.1009    38.8679   54.2167       
                                      Total          1820    49.1430    100.000                  
       Female        Tertile 1: <19.5 ng/mL           975    17.2424    33.9038   56.3965       
                 Tertile 2: 19.5-26.2 ng/mL           545    17.4848    34.3804   51.1314       
                     Tertile 3: >26.2 ng/mL           360    16.1297    31.7159   45.7833       
                                      Total          1880    50.8570    100.000                  
        Total        Tertile 1: <19.5 ng/mL          1748    30.5736              100.000       
                 Tertile 2: 19.5-26.2 ng/mL          1133    34.1958              100.000       
                     Tertile 3: >26.2 ng/mL           819    35.2306              100.000       
                                      Total          3700    100.000                             
                               Rao-Scott Modified Chi-Square Test                                
                                 Pearson Chi-Square    27.3535                                   
                                 Design Correction      1.4178                                   
                                 Rao-Scott Chi-Square  19.2935                                   
                                 DF                          2                                   
                                 Pr > ChiSq             <.0001                                   
                                 F Value                9.6468                                   
                                 Num DF                      2                                   
                                 Den DF                     90                                   
                                 Pr > F                 0.0002   
 Table of race by vtert                                      
                                                                     Row       Column 
                    race                        vtert    Frequency   Percent   Percent 
ercent 
----------------------------------------------------------------------------------------- 
     Non-hispanic white       Tertile 1: <19.5 ng/mL    141    9.0061   14.5805  9.4570 
                           Tertile 2: 19.5-26.2 ng/m    353   22.6946   36.7418   66.3666 
                               Tertile 3: >26.2 ng/mL   491   30.0671   48.6776   85.3437 
   Total          985   61.7677   100.000           
      Non-hispanic black       Tertile 1: <19.5 ng/mL   902   10.7697   73.9413   35.2255 
                           Tertile 2: 19.5-26.2 ng/mL   239    2.8262   19.4037    8.2647 
                               Tertile 3: >26.2 ng/mL   85    0.9693    6.6550    2.7514 
   Total         1226   14.5652   100.000           
Hispnic/Mexican American       Tertile 1: <19.5 ng/mL   624    7.5480   42.8855   24.6880 
                           Tertile 2: 19.5-26.2 ng/mL   492    6.8963   39.1825   20.1671 
                               Tertile 3: >26.2 n       217    3.1561   17.9320    8.9585 
         Total   1333   17.6004   100.000           
                   Other       Tertile 1: <19.5 ng/mL   81    3.2498   53.5688   10.6295 
                           Tertile 2: 19.5-26.2 ng/mL   49    1.7787   29.3202    5.2016 
                               Tertile 3: >26.2 ng/mL    26    1.0381   17.1111    2.9465 
           Total          156    6.0666   100.000           
                   Total       Tertile 1: <19.5 ng/mL         1748   30.5736             
100.000 
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                           Tertile 2: 19.5-26.2 ng/mL  1133   34.1958             100.000 
                               Tertile 3: >26.2 ng/m   819   35.2306             100.000 
          Total         3700   100.000                     
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
ƒƒƒƒƒƒƒ Table of race by vtert                                      
Rao-Scott Modified Chi-Square Test              Pearson Chi-Square    957.3708                                  
                              Design Correction       2.5486                                  
                               Rao-Scott Chi-Square  375.6431                                  
                               DF                           6                                  
                               Pr > ChiSq              <.0001                                  
                                                                                                
                               F Value                62.6072                                  
                               Num DF                       6                                  
                               Den DF                     270                                  
                               Pr > F                  <.0001                                  
Table of age by vtert     
                                                                           Row     Column        
         age                         vtert     Frequency    Percent    Percent    Percent        
      ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ        
      12-14y        Tertile 1: <19.5 ng/mL           869    15.3010    30.4932    50.0464        
                Tertile 2: 19.5-26.2 ng/mL           589    17.1889    34.2555    50.2660        
                    Tertile 3: >26.2 ng/mL           401    17.6886    35.2513    50.2080        
                                                                                                 
                                     Total          1859    50.1784    100.000                   
      -----------------------------------------------------------------------------------        
      15-17y        Tertile 1: <19.5 ng/mL           879    15.2726    30.6546    49.9536        
                Tertile 2: 19.5-26.2 ng/mL           544    17.0070    34.1357    49.7340        
                    Tertile 3: >26.2 ng/mL           418    17.5420    35.2097    49.7920        
Total          1841    49.8216    100.000                   
      -----------------------------------------------------------------------------------        
       Total        Tertile 1: <19.5 ng/mL          1748    30.5736               100.000        
                Tertile 2: 19.5-26.2 ng/mL          1133    34.1958               100.000        
                    Tertile 3: >26.2 ng/mL           819    35.2306               100.000        
Total          3700    100.000                              
      ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ        
                               Rao-Scott Modified Chi-Square Test                                
                                  Pearson Chi-Square    0.0122                                   
                                  Design Correction     2.0214                                   
                                  Rao-Scott Chi-Square  0.0060                                   
                                  DF                         2                                   
                                  Pr > ChiSq            0.9970                                   
                                  F Value               0.0030                                   
                                  Num DF                     2                                   
                                  Den DF                    90                                   
                                  Pr > F                0.9970                                   
Sample Size = 3700                                        
Table of RIDEXMON by vtert                                   
                                                                           Row     Column       
     RIDEXMON                         vtert     Frequency    Percent    Percent    
Percent       
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ       
       winter        Tertile 1: <19.5 ng/mL    1094    17.5381    42.6311    57.3637       
                 Tertile 2: 19.5-26.2 ng/mL    577    14.2560    34.6529    41.6892       
                     Tertile 3: >26.2 ng/mL    280     9.3452    22.7160    26.5259       
 Total          1951    41.1393    100.000                  
       summer        Tertile 1: <19.5 ng/mL    654    13.0355    22.1463    42.6363       
                 Tertile 2: 19.5-26.2 ng/mL    556    19.9399    33.8764    58.3108       
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                     Tertile 3: >26.2 ng/mL   539    25.8853    43.9773    73.4741       
 Total          1749    58.8607    100.000             
        Total        Tertile 1: <19.5 ng/mL   1748    30.5736               100.000       
                 Tertile 2: 19.5-26.2 ng/mL   1133    34.1958               100.000       
                     Tertile 3: >26.2 ng/mL   819    35.2306               100.000       
 Total          3700    100.000                             
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ       
                               Rao-Scott Modified Chi-Square Test                                
                                                                                                
                                 Pearson Chi-Square    238.0872                                  
                                 Design Correction       4.4249                                  
                                                                                                 
                                 Rao-Scott Chi-Square   53.8059                                  
                                 DF                           2                                  
                                 Pr > ChiSq              <.0001                                  
                                                                                                 
                                 F Value                26.9029                                  
                                 Num DF                       2                                  
                                 Den DF                      90                                  
                                 Pr > F                  <.0001                                  
                                                                                                
Table of bmigroup by vtert                                    
                                                                          Row     Column 
                        bmigroup              vtert   Frequency  Percent  Percent Percent      
Normal wt: <85th percentile   Tertile 1: <19.5 ng/mL   1408  24.6569  27.8741  81.2827            
                              Tertile 2: 19.5-26.2 ng/mL  1011  30.8415  34.8657 89.8285            
                             Tertile 3: >26.2 ng/mL        762   32.9596  37.2602 93.2871            
     Total        3181  88.4581  100.000 
Overweight and obese:>=85th percentileTertile 1: <19.5 ng/mL 319  5.6778  49.1934 18.7173            
                                 Tertile 2: 19.5-26.2 ng/mL 118  3.4923  30.2574 10.1715            
                                 Tertile 3: >26.2 ng/mL      54  2.3718  20.5492  6.7129            
  Total       491 11.5419  100.000 100.000 
                                 Total  Tertile 1: <19.5 ng/mL    1727  30.3348     
                                        Tertile 2: 19.5-26.2 ng/mL    1129  34.3338   
                                        Tertile 3: >26.2 ng/mL    816  35.3314                                                   
                          Total    3672  100.000  100.000        
                                     Frequency Missing = 28                                      
                                 Rao-Scott Modified Chi-Square Test                                
                                        
                                 Pearson Chi-Square    88.1228                                   
                                 Design Correction      1.7194                                   
                                                                                                 
                                 Rao-Scott Chi-Square  51.2518                                   
                                 DF                          2                                   
                                 Pr > ChiSq             <.0001                                   
                                                                                                 
                                 F Value               25.6259                                   
                                 Num DF                      2                                   
                                 Den DF                     90                                   
                                 Pr > F                 <.0001                                   
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APPENDIX D 
 
SAMPLE SIZE OF VARIABLES ACCORDING TO SERUM 
VITAMIN D TERTILE CATEGORIES 
  
Table of age by vstatus2 
age       vstatus2 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚    869 ‚    589 ‚    401 ‚   1859 
       2 ‚    879 ‚    544 ‚    418 ‚   1841 
Total        1748     1133      819     3700 
 
Table of RIAGENDR by vstatus2 
RIAGENDR(Gender)     vstatus2 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚    773 ‚    588 ‚    459 ‚   1820 
       2 ‚    975 ‚    545 ‚    360 ‚   1880 
Total        1748     1133      819     3700 
 
Table of race by vstatus2 
race      vstatus2 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚    141 ‚    353 ‚    491 ‚    985 
       2 ‚    902 ‚    239 ‚     85 ‚   1226 
       3 ‚    624 ‚    492 ‚    217 ‚   1333 
       4 ‚     81 ‚     49 ‚     26 ‚    156 
Total        1748     1133      819     3700 
 
Table of pir by vstatus2 
pir       vstatus2 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚    566 ‚    291 ‚    132 ‚    989 
       2 ‚    641 ‚    366 ‚    252 ‚   1259 
       3 ‚    452 ‚    433 ‚    395 ‚   1280 
       4 ‚     89 ‚     43 ‚     40 ‚    172 
Total        1748     1133      819     3700 
 
Table of RIDEXMON by vstatus2 
RIDEXMON(Six month time period)     vstatus2 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚   1094 ‚    577 ‚    280 ‚   1951 
       2 ‚    654 ‚    556 ‚    539 ‚   1749 
Total        1748     1133      819     3700 
 
Table of DSD010 by vstatus2 
DSD010(Any dietary supplements taken?) 
         vstatus2 
Frequency‚       1‚       2‚       3‚  Total 
       1 ‚    247 ‚    255 ‚    212 ‚    714 
       2 ‚   1499 ‚    878 ‚    607 ‚   2984 
       3 ‚      2 ‚      0 ‚      0 ‚      2 
Total        1748     1133      819     3700 
 
Table of bmigroup by vstatus2 
bmigroup     vstatus2 
Frequency‚       1‚       2‚       3‚  Total 
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       1 ‚   1408 ‚   1011 ‚    762 ‚   3181 
       2 ‚    319 ‚    118 ‚     54 ‚    491 
       3 ‚     21 ‚      4 ‚      3 ‚     28 
Total        1748     1133      819     3700 
 
|  Variable                       |                  | VSTATUS2                                          
| 
|                 |                  | Total      | 1          | 2          | 3           
| AGE: 1          | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |      50.18 |      50.05 |      50.27 |      50.21 
|| Gender: 1       | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |      49.14 |      43.60 |      48.87 |      54.22 
|| RACE: 1         | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |      61.77 |      29.46 |      66.37 |      85.34 
|| PIR: 1          | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |      17.40 |      25.72 |      16.87 |      10.70 
|| Six month time  | Sample size      |       3700 |       1748 |       1133 |        819 
|| period: 1       | Percent          |      41.14 |      57.36 |      41.69 |      26.53 
|| Any dietary     | Sample size      |       3700 |       1748 |       1133 |        819 
|| supplements     | Percent          |      24.13 |      17.84 |      25.27 |      28.48 
|| taken?: 1       |                  |            |            |            |            
|| BMIGROUP: 1     | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |      87.89 |      80.13 |      89.61 |      92.95  
| AGE: 2          | Sample size      |       3700 |       1748 |       1133 |        819  
|                 | Percent          |      49.82 |      49.95 |      49.73 |      49.79 
|| Gender: 2       | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |      50.86 |      56.40 |      51.13 |      45.78 
|| RACE: 2         | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |      14.57 |      35.23 |       8.26 |       2.75 
|| PIR: 2          | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |      28.79 |      33.08 |      28.09 |      25.74 
|| Six month time  | Sample size      |       3700 |       1748 |       1133 |        819 
|| period: 2       | Percent          |      58.86 |      42.64 |      58.31 |      73.47 
|| Any dietary     | Sample size      |       3700 |       1748 |       1133 |        819 
|| supplements     | Percent          |      75.81 |      81.96 |      74.73 |      71.52 
|| taken?: 2       |                  |            |            |            |            
|| BMIGROUP: 2     | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |      11.47 |      18.45 |      10.15 |       6.69  
| RACE: 3         | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |      17.60 |      24.69 |      20.17 |       8.96 
|| PIR: 3          | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |      49.98 |      36.83 |      52.84 |      58.61 
|| Any dietary     | Sample size      |       3700 |       1748 |       1133 |        819 
|| supplements     | Percent          |       0.06 |       0.20 |       0.00 |       0.00 
|| taken?: 3       |                  |            |            |            |            
|| BMIGROUP: 3     | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |       0.64 |       1.42 |       0.24 |       0.36  
| RACE: 4         | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |       6.07 |      10.63 |       5.20 |       2.95 
|| PIR: 4          | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |       3.84 |       4.37 |       2.21 |       4.95  
                                   Cumulative    Cumulative                                          
vstatus2    Frequency     Percent     Frequency      Percent                                           
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ                                          
       1        1748       47.24          1748        47.24                                            
       2        1133       30.62          2881        77.86                                            
       3         819       22.14          3700       100.00                                             
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APPENDIX E  
 
ASSOCIATION BETWEEEN SERUM VITAMIN D AND 
CONCENTRATIONS AND PREVALENCE OF METABOLIC 
SYNDROME 
 
Table of vstatus2 by metsyn 
vstatus2     metsyn 
Frequency‚       0‚       1‚  Total 
       1 ‚   1617 ‚    131 ‚   1748 
       2 ‚   1077 ‚     56 ‚   1133 
       3 ‚    793 ‚     26 ‚    819 
Total        3487      213     3700 
 
Table of vstatus2 by metsyn 
vstatus2     metsyn 
Frequency‚       0‚       1‚  Total 
       1 ‚    201 ‚    118 ‚    319 
       2 ‚     81 ‚     37 ‚    118 
       3 ‚     37 ‚     17 ‚     54 
Total         319      172      491 
-- 
| Variable                        |                  | VSTATUS2                                           
|                 |                  | Total      | 1          | 2          | 3           
| METSYN: 1       | Sample size      |       3700 |       1748 |       1133 |        819 
||                 | Percent          |       6.07 |       8.71 |       6.36 |       3.50 
|| METSYN: 1       | Sample size      |        491 |        319 |        118 |         54 
||for BMI≥85th percentile | Percent    |      39.07 |      41.96 |      38.58 |      32.85 
|---------------------------------------------------------------------------------------- 
 
LOGISTIC REGRESSION  
Number of observations read       :  30070    Weighted count:285937478 
Observations in subpopulation     :   3444    Weighted count: 16630443 
Observations used in the analysis :   3444    Weighted count: 16630443 
R-Square for dependent variable METSYN (Cox & Snell, 1989): 0.146248 
-2 * Normalized Log-Likelihood with Intercepts Only :  1511.06 
-2 * Normalized Log-Likelihood Full Model           :   966.51 
Approximate Chi-Square (-2 * Log-L Ratio)           :   544.55 
Degrees of Freedom                                  :       11 
Response variable METSYN: METSYN 
For Subpopulation: SUBGROUP = 1 by: Independent Variables and Effects. 
-------------------------------------------------------------------------- 
Independent                                                                             
P-value 
  Variables and        Beta                      Lower 95%    Upper 95%                 
T-Test 
  Effects              Coeff.          SE Beta   Limit Beta   Limit Beta   T-Test B=0   
B=0 
-------------------------------------------------------------------------- 
Intercept           -0.99         1.33        -3.67         1.69        -0.75     0.4596 
VSTATUS 
  1                  0.82         0.35         0.10         1.53         2.31     0.0258 
  2                  0.77         0.31         0.13         1.40         2.43     0.0190 
  3                  0.00         0.00         0.00         0.00           
Gender 
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  1                  0.79         0.21         0.37         1.22         3.74     0.0005 
  2                  0.00         0.00         0.00         0.00           
RACE 
  1                  0.00         0.00         0.00         0.00           
  2                 -2.35         0.67        -3.70        -1.01        -3.52     0.0010 
  3                 -1.66         0.40        -2.47        -0.85        -4.13     0.0002 
  4                 -1.06         0.93        -2.93         0.81        -1.14     0.2611 
Age at Screening 
  Adjudicated - 
  Recode            0.03         0.07        -0.11         0.18         0.48     0.6339 
BMIGROUP 
  1                 3.29         0.36        -4.01        -2.56        -9.15     0.0000 
  2                 0.00         0.00         0.00         0.00           
BMIRACE 
  0                -0.86         1.26        -3.39         1.68        -0.68     0.4990 
  1                 0.42         1.28        -2.16         2.99         0.33     0.7462 
  2                 0.81         1.31        -1.84         3.46         0.62     0.5402 
  3                 0.00         0.00         0.00         0.00           
-------------------------------------------------------------------------- 
Contrast               Degrees 
                       of                      P-value 
                       Freedom        Wald F   Wald F 
------------------------------------------------------- 
OVERALL MODEL                12        75.29     0.0000 
MODEL MINUS 
  INTERCEPT                  11        30.30     0.0000 
INTERCEPT                     .          .        . 
VSTATUS                       2         3.45     0.0404 
RIAGENDR                      1        13.97     0.0005 
RACE                          3         8.00     0.0002 
RIDAGEYR                      1         0.23     0.6339 
BMIGROUP                      1        83.73     0.0000 
BMIRACE                       3         3.40     0.0257 
------------------------------------------------------- 
Independent 
  Variables and                     Lower 95%    Upper 95% 
  Effects              Odds Ratio   Limit OR     Limit OR 
----------------------------------------------------------- 
Intercept                    0.37         0.03         5.39 
VSTATUS 
  1                          2.26         1.11         4.61 
  2                          2.15         1.14         4.05 
  3                          1.00         1.00         1.00 
Gender 
  1                          2.21         1.44         3.40 
  2                          1.00         1.00         1.00 
RACE 
  1                          1.00         1.00         1.00 
  2                          0.09         0.02         0.36 
  3                          0.19         0.08         0.43 
  4                          0.35         0.05         2.26 
Age at Screening 
  Adjudicated - 
  Recode                     1.03         0.90         1.19 
BMIGROUP 
  1                          0.04         0.02         0.08 
  2                          1.00         1.00         1.00 
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BMIRACE 
  0                          0.42         0.03         5.35 
  1                          1.52         0.12        19.88 
  2                          2.25         0.16        31.81 
  3                          1.00         1.00         1.00 
----------------------------------------------------------- 
LOGISTIC REGRESSION FOR SUBJECTS WITH ≥85th PERCENTILE 
 
Number of observations read       :  30070    Weighted count:285937478 
Observations in subpopulation     :    441    Weighted count:  1868574 
Observations used in the analysis :    441    Weighted count:  1868574 
R-Square for dependent variable METSYN (Cox & Snell, 1989): 0.082810 
Response variable METSYN: METSYN 
For Subpopulation: SUBGROUPBMI = 1 by: Independent Variables and Effects. 
-------------------------------------------------------------------------- 
Independent                                                                             
P-value 
  Variables and        Beta                      Lower 95%    Upper 95%                 
T-Test 
  Effects              Coeff.          SE Beta   Limit Beta   Limit Beta   T-Test B=0   
B=0 
-------------------------------------------------------------------------- 
Intercept           -2.61         1.50        -5.64         0.42        -1.74     0.0892 
VSTATUS 
  1                  0.72         0.49        -0.27         1.70         1.47     0.1483 
  2                  0.40         0.48        -0.57         1.38         0.84     0.4072 
  3                  0.00         0.00         0.00         0.00          .        . 
Gender 
  1                 0.84         0.27         0.30         1.39         3.10     0.0033 
  2                 0.00         0.00         0.00         0.00          RACE 
  1                 0.00         0.00         0.00         0.00          .        . 
  2                 1.15         0.35        -1.86        -0.44        -3.27     0.0021 
  3                 0.02         0.34        -0.67         0.71         0.05     0.9607 
  4                 0.31         0.79        -1.89         1.28        -0.39     0.6994 
Age at Screening 
  Adjudicated - 
  Recode            0.10         0.11        -0.12         0.31         0.92     0.3638 
-------------------------------------------------------------------------- 
Contrast               Degrees 
                       of                      P-value 
                       Freedom        Wald F   Wald F 
------------------------------------------------------- 
OVERALL MODEL                 8         8.19     0.0000 
MODEL MINUS 
  INTERCEPT                   7         4.34     0.0010 
INTERCEPT                     .          .        . 
VSTATUS                       2         1.12     0.3347 
RIAGENDR                      1         9.60     0.0033 
RACE                          3         5.86     0.0018 
RIDAGEYR                      1         0.84     0.3638 
------------------------------------------------------- 
Independent 
  Variables and                     Lower 95%    Upper 95% 
  Effects              Odds Ratio   Limit OR     Limit OR 
----------------------------------------------------------- 
Intercept                    0.07         0.00         1.52 
VSTATUS 
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  1                          2.05         0.77         5.49 
  2                          1.50         0.57         3.97 
  3                          1.00         1.00         1.00 
Gender 
  1                          2.33         1.34         4.03 
  2                          1.00         1.00         1.00 
RACE 
  1                          1.00         1.00         1.00 
  2                          0.32         0.15         0.64 
  3                          1.02         0.51         2.03 
  4                          0.74         0.15         3.59 
Age at Screening 
  Adjudicated - 
  Recode                     1.10         0.89         1.36 
-----------------------------------------------------------  
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APPENDIX F  
 
ADJUSTED CONCENTRATIONS OF INDICATORS OF 
METABOLIC SYNDROME ACCORDING TO TERTILES OF 
SERUM VITAMIN D IN 12-17y OLD CHOLDREN AND 
ADOLESCENTS IN NHANES 2001-2006 
 
Number of observations read       :  30070    Weighted count:285937478 
Observations in subpopulation     :    773    Weighted count:  3322590 
Observations used in the analysis :    773    Weighted count:  3322590 
Weighted mean response is -1.789071 
Multiple R-Square for the dependent variable LOGCRP: 0.027673 
Response variable LOGCRP: LOGCRP 
For Subpopulation: CRPBMI = 1 by: Independent Variables and Effects. 
Independent                                                                             
P-value 
  Variables and        Beta                      Lower 95%    Upper 95%                 
T-Test  Effect Coeff SE Beta   Limit Beta   Limit Beta   T-Test B=0   B=0 
Intercept 
 -1.91         0.23        -2.37        -1.46        -8.41     0.0000 
VSTATUS 
  1            -0.02         0.19        -0.41         0.37        -0.10     0.9178 
  2            -0.22         0.17        -0.56         0.13        -1.24     0.2205 
  3            0.00         0.00         0.00         0.00          .        . 
RACE 
  1            0.15         0.23        -0.32         0.62         0.63     0.5338 
  2            0.30         0.19        -0.09         0.68         1.54     0.1312 
  3            0.34         0.23        -0.12         0.80         1.49     0.1428 
  4            0.00         0.00         0.00         0.00          .        . 
NEWAGE         0.09         0.03         0.02         0.15         2.74     0.0088 
-------------------------------------------------------------------------- 
Contrast               Degrees 
                       of                      P-value 
                       Freedom        Wald F   Wald F 
------------------------------------------------------- 
OVERALL MODEL                 7       180.71     0.0000 
MODEL MINUS 
  INTERCEPT                   6         2.64     0.0282 
INTERCEPT                     .          .        . 
VSTATUS                       2         1.45     0.2460 
RACE                          3         1.19     0.3237 
NEWAGE                        1         7.51     0.0088 
------------------------------------------------------- 
Conditional Marginal   Condition- 
  #1                   al 
                       Marginal             SE     T:Marg=0    P-value 
---------------------------------------------------------------------- 
VSTATUS 
  1                         -1.73         0.11       -15.87     0.0000 
  2                         -1.92         0.10       -18.73     0.0000 
  3                         -1.71         0.14       -12.60     0.0000 
---------------------------------------------------------------------- 
Contrasted 
  Conditional          CONDMARG 
  Marginal #1          Contrast             SE       T-Stat    P-value 
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---------------------------------------------------------------------- 
COND_EFF Contrast #  1  0.19         0.14         1.42     0.1622 
COND_EFF Contrast #  2 -0.02         0.19        -0.10     0.9178 
COND_EFF Contrast #  3  0.22         0.17        -1.24     0.2205 
---------------------------------------------------------------------- 
 
LOGCRP LINEAR REGRESSION  
Number of observations read       :  30070    Weighted count:285937478 
Observations in subpopulation     :   4414    Weighted count: 21553668 
Observations used in the analysis :   4414    Weighted count: 21553668 
Weighted mean response is -3.059159 
Multiple R-Square for the dependent variable LOGCRP: 0.168923 
Response variable LOGCRP: LOGCRP 
For Subpopulation: CRPVITD = 1 by: Independent Variables and Effects. 
--------------------------------------------------------------------------Independent                                                                             
P-value 
  Variables and        Beta                      Lower 95%    Upper 95%                 
T-Test 
  Effects              Coeff.          SE Beta   Limit Beta   Limit Beta   T-Test B=0   
B=0 
-----------------------------------------------------------------------------------------
Intercept          -1.89         0.13        -2.15        -1.63       -14.66     0.0000 
VSTATUS 
  1                -0.14         0.07        -0.28         0.01        -1.84     0.0719 
  2                -0.03         0.06        -0.16         0.09        -0.59     0.5609 
  3                 0.00         0.00         0.00         0.00          .        . 
RACE 
  1                 0.07         0.11        -0.15         0.30         0.63     0.5291 
  2                 0.14         0.10        -0.06         0.33         1.40     0.1676 
  3                 0.30         0.10         0.10         0.50         3.06     0.0038 
  4                 0.00         0.00         0.00         0.00          .        . 
BMIGROUP 
  1                -1.50         0.07        -1.65        -1.36       -20.88     0.0000 
  2                 0.00         0.00         0.00         0.00          .        . 
PIR 
  1                 0.16         0.06         0.03         0.29         2.54     0.0144 
  2                 0.04         0.06        -0.09         0.16         0.58     0.5629 
  3                 0.00         0.00         0.00         0.00          .        . 
NEWAGE              0.09         0.02         0.06         0.12         6.17     0.0000 
-------------------------------------------------------------------------- 
Contrast               Degrees 
                       of                      P-value 
                       Freedom        Wald F   Wald F 
------------------------------------------------------- 
OVERALL MODEL                10      2020.33     0.0000 
MODEL MINUS 
  INTERCEPT                   9        84.63     0.0000 
INTERCEPT                     .          .        . 
VSTATUS                       2         1.78     0.1801 
RACE                          3         7.94     0.0002 
BMIGROUP                      1       436.17     0.0000 
PIR                           2         3.27     0.0473 
NEWAGE                        1        38.04     0.0000 
---------------------------------------------------------------------- 
Conditional Marginal   Condition- 
  #1                   al 
                       Marginal             SE     T:Marg=0    P-value 
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---------------------------------------------------------------------- 
VSTATUS 
  1                         -3.14         0.05       -58.78     0.0000 
  2                         -3.04         0.04       -69.74     0.0000 
  3                         -3.01         0.04       -70.77     0.0000 
---------------------------------------------------------------------- 
COND_EFF Contrast #  1     -0.10         0.07        -1.50     0.1415 
COND_EFF Contrast #  2     -0.14         0.07        -1.84     0.0719 
COND_EFF Contrast #  3     -0.03         0.06        -0.59     0.5609 
---------------------------------------------------------------------- 
 
LOGHOMA LINEAR REGRESSION 
Number of observations read       :  30070    Weighted count:285937478 
Observations in subpopulation     :   2184    Weighted count: 10355404 
Observations used in the analysis :   2184    Weighted count: 10355404 
Weighted mean response is 0.880053 
Multiple R-Square for the dependent variable LOGHOMA: 0.229754 
Response variable LOGHOMA: LOGHOMA 
For Subpopulation: HOMAVITD = 1 by: Independent Variables and Effects. 
-----------------------------------------------------------------------------------------
---- 
Independent                                                                             
P-value 
  Variables and        Beta                      Lower 95%    Upper 95%                 
T-Test 
  Effects              Coeff.          SE Beta   Limit Beta   Limit Beta   T-Test B=0   
B=0 
-----------------------------------------------------------------------------------------
Intercep1.61        0.12     1.37         1.84        13.79     0.0000 
VSTATUS 
  1                 0.14     0.04         0.06         0.22         3.43     0.0013 
  2                 0.06     0.04        -0.03         0.15         1.39     0.1715 
  3                 0.00     0.00        0.00         0.00         .     
RACE 
  1                 0.05         0.08        -0.21         0.11        -0.65     0.5167 
  2                -0.11         0.08        -0.27         0.06        -1.33     0.1916 
  3                -0.02         0.08        -0.19         0.14        -0.28     0.7790 
  4                 0.00         0.00         0.00         0.00          .        . 
BMIGROUP 
  1                -0.84         0.06        -0.96        -0.73       -14.59     0.0000 
  2                 0.00         0.00         0.00         0.00          .        . 
Any dietary 
  supplements taken? 
  1                -0.09         0.04        -0.18        -0.01        -2.13     0.0389 
  2                 0.00         0.00         0.00         0.00          .        . 
-----------------------------------------------------------------------------------------
------- 
Contrast               Degrees 
                       of                      P-value 
                       Freedom        Wald F   Wald F 
------------------------------------------------------- 
OVERALL MODEL                 8       508.75     0.0000 
MODEL MINUS 
  INTERCEPT                   7        36.61     0.0000 
INTERCEPT                     .          .        . 
VSTATUS                       2         6.28     0.0039 
RACE                          3         2.11     0.1124 
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BMIGROUP                      1       212.92     0.0000 
DSD010                        1         4.52     0.0389 
---------------------------------------------------------------------- 
Conditional Marginal   Condition- 
  #1                   al 
                       Marginal             SE     T:Marg=0    P-value 
---------------------------------------------------------------------- 
VSTATUS 
  1                          0.95         0.03        35.95     0.0000 
  2                          0.87         0.03        29.01     0.0000 
  3                          0.81         0.03        23.57     0.0000 
---------------------------------------------------------------------- 
Contrasted 
  Conditional          CONDMARG 
  Marginal #1          Contrast             SE       T-Stat    P-value 
--------------------------------------------------------------------- 
COND_EFF Contrast #  1  0.08         0.04         2.17     0.0350 
COND_EFF Contrast #  2  0.14         0.04         3.43     0.0013 
COND_EFF Contrast #  3  0.06         0.04         1.39     0.1715 
---------------------------------------------------------------------- 
 
LOGGLU LINEAR REGRESSSION 
 
Number of observations read       :  30070    Weighted count:285937478 
Observations in subpopulation     :   2206    Weighted count: 10446523 
Observations used in the analysis :   2206    Weighted count: 10446523 
Weighted mean response is 4.532903 
Multiple R-Square for the dependent variable LOGGLU: 0.093170 
Response variable LOGGLU: LOGGLU 
For Subpopulation: GLUVITD = 1 by: Independent Variables and Effects. 
-----------------------------------------------------------------------------------------
------- 
Independent                                                                             
P-value 
  Variables and        Beta                      Lower 95%    Upper 95%                 
T-Test 
  Effects              Coeff.          SE Beta   Limit Beta   Limit Beta   T-Test B=0   
B=0 
-----------------------------------------------------------------------------------------
------- 
Intercept          4.54         0.02         4.49         4.58       204.55     0.0000 
VSTATUS 
  1               0.01         0.01        -0.01         0.03         1.39     0.1721 
  2               0.01         0.01        -0.01         0.03         1.07     0.2918 
  3               0.00         0.00         0.00         0.00          .        . 
Gender 
  1               0.06         0.01         0.04         0.07         7.43     0.0000 
  2               0.00         0.00         0.00         0.00          .        . 
RACE 
  1              -0.01         0.02        -0.04         0.03        -0.38     0.7078 
  2              -0.05         0.01        -0.08        -0.02        -3.94     0.0003 
  3              -0.01         0.01        -0.04         0.01        -0.98     0.3315 
  4               0.00         0.00         0.00         0.00          .        . 
BMIGROUP 
  1              -0.03         0.01        -0.05        -0.01        -2.48     0.0171 
  2               0.00         0.00         0.00         0.00          .        . 
Six month time 
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  period 
  1              -0.01         0.01        -0.02         0.00        -1.87     0.0680 
  2               0.00         0.00         0.00         0.00          .        . 
NEWAGE            0.01         0.00        -0.01        -0.00        -3.77     0.0005 
-----------------------------------------------------------------------------------------
Contrast               Degrees 
                       of                      P-value 
                       Freedom        Wald F   Wald F 
------------------------------------------------------- 
OVERALL MODEL                10    300552.16     0.0000 
MODEL MINUS 
  INTERCEPT                   9        14.86     0.0000 
INTERCEPT                     .          .        . 
VSTATUS                       2         0.96     0.3895 
RIAGENDR                      1        55.27     0.0000 
RACE                          3        11.75     0.0000 
BMIGROUP                      1         6.14     0.0171 
RIDEXMON                      1         3.50     0.0680 
NEWAGE                        1        14.21     0.0005 
------------------------------------------------------- 
Conditional Marginal   Condition- 
  #1                   al 
                       Marginal             SE     T:Marg=0    P-value 
---------------------------------------------------------------------- 
VSTATUS 
  1                          4.54         0.01       794.84     0.0000 
  2                          4.54         0.01       727.66     0.0000 
  3                          4.52         0.01       618.50     0.0000 
---------------------------------------------------------------------- 
Contrasted 
  Conditional          CONDMARG 
  Marginal #1          Contrast             SE       T-Stat    P-value 
---------------------------------------------------------------------- 
COND_EFF Contrast #   1      0.00         0.01         0.46     0.6511 
COND_EFF Contrast #   2      0.01         0.01         1.39     0.1721 
COND_EFF Contrast #   3      0.01         0.01         1.07     0.2918 
---------------------------------------------------------------------- 
BMXWAIST LINEAR REGRESSION 
 
Number of observations read       :  30070    Weighted count:285937478 
Observations in subpopulation     :   4591    Weighted count: 22277006 
Observations used in the analysis :   4591    Weighted count: 22277006 
Multiple R-Square for the dependent variable BMXWAIST: 0.091219 
Response variable BMXWAIST: Waist Circumference (cm) 
For Subpopulation: WCVITD = 1 by: Independent Variables and Effects. 
----------------------------------------------------------------------------------------- 
Independent                                                                             
P-value 
  Variables and        Beta                      Lower 95%    Upper 95%                 
T-Test 
  Effects              Coeff.          SE Beta   Limit Beta   Limit Beta   T-Test B=0   
B=0 
-----------------------------------------------------------------------------------------
------- 
Intercept           71.23         1.19        68.84        73.62        60.05     0.0000 
VSTATUS 
  1                 8.10         0.87         6.35         9.86         9.30     0.0000 
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  2                  3.51         0.47         2.57         4.45         7.52     0.0000 
  3                  0.00         0.00         0.00         0.00          .        . 
RACE  1              6.80         1.20         4.37         9.22         5.64     0.0000 
  2                  1.55         1.01        -0.48         3.58         1.54     0.1303 
  3                  6.45         1.08         4.27         8.63         5.96     0.0000 
  4                  0.00         0.00         0.00         0.00          .        . 
Gender 
  1                  1.45         0.56         0.31         2.58         2.57     0.0135 
  2                  0.00         0.00         0.00         0.00          .        . 
Six month time 
  period 
  1                -1.98         0.64        -3.27        -0.70        -3.11     0.0033 
  2                 0.00         0.00         0.00         0.00          .        . 
Any dietary 
  supplements taken? 
  1                -2.00         0.53        -3.06        -0.95        -3.81     0.0004 
  2                 0.00         0.00         0.00         0.00          .        . 
NEWAGE              1.54         0.18         1.17         1.90         8.41     0.0000 
----------------------------------------------------------------------- 
Contrast               Degrees 
                       of                      P-value 
                       Freedom        Wald F   Wald F 
------------------------------------------------------- 
OVERALL MODEL                10     13713.86     0.0000 
MODEL MINUS 
  INTERCEPT                   9        68.11     0.0000 
INTERCEPT                     .          .        . 
VSTATUS                       2        56.84     0.0000 
RACE                          3        32.16     0.0000 
RIAGENDR                      1         6.61     0.0135 
RIDEXMON                      1         9.64     0.0033 
DSD010                        1        14.54     0.0004 
NEWAGE                        1        70.81     0.0000 
--------------------------------------------------------------------- 
Conditional Marginal   Condition- 
  #1                   al 
                       Marginal             SE     T:Marg=0    P-value 
---------------------------------------------------------------------- 
VSTATUS 
  1                         84.41         0.71       118.40     0.0000 
  2                         79.81         0.41       192.58     0.0000 
  3                         76.30         0.48       157.92     0.0000 
Contrasted 
  Conditional          CONDMARG 
  Marginal #1          Contrast             SE       T-Stat    P-value 
---------------------------------------------------------------------- 
COND_EFF Contrast #  1       4.59         0.87         5.28     0.0000 
COND_EFF Contrast #  2       8.10         0.87         9.30     0.0000 
COND_EFF Contrast #  3       3.51         0.47         7.52     0.0000 
---------------------------------------------------------------------- 
LOGHDD LINEAR REGRESSION 
Number of observations read       :  30070    Weighted count:285937478 
Observations in subpopulation     :   4404    Weighted count: 21499913 
Observations used in the analysis :   4404    Weighted count: 21499913 
Response variable LOGHDD: LOGHDD 
For Subpopulation: HDLVITD = 1 by: Independent Variables and Effects. 
----------------------------------------------------------------------------------------- 
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Independent                                                                             
P-value 
  Variables and        Beta                      Lower 95%    Upper 95%                 
T-Test 
  Effects              Coeff.          SE Beta   Limit Beta   Limit Beta   T-Test B=0   
B=0 
-----------------------------------------------------------------------------------------
------- 
Intercept           3.94         0.04         3.87         4.01       110.85     0.0000 
VSTATUS  1         -0.06         0.01        -0.08        -0.03        -4.46     0.0001 
  2                -0.06         0.01        -0.08        -0.04        -5.45     0.0000 
  3                 0.00         0.00         0.00         0.00          .        . 
BMIGROUP 
  1                 0.17         0.01         0.15         0.20        15.45     0.0000 
  2                 0.00         0.00         0.00         0.00          .        . 
PIR 
  1                -0.04         0.01        -0.07        -0.01        -2.88     0.0061 
  2                -0.02         0.01        -0.04         0.01        -1.34     0.1864 
  3                 0.00         0.00         0.00         0.00          .        . 
NEWAGE             -0.01         0.00        -0.01        -0.00        -2.43     0.0191 
Gender, RACE 
  1, 1             -0.22         0.03        -0.28        -0.15        -6.63     0.0000 
  1, 2             -0.04         0.03        -0.11         0.02        -1.27     0.2093 
  1, 3             -0.13         0.03        -0.19        -0.08        -4.59     0.0000 
  1, 4             -0.16         0.04        -0.24        -0.08        -4.07     0.0002 
  2, 1             -0.10         0.03        -0.17        -0.03        -2.93     0.0053 
  2, 2             -0.00         0.03        -0.07         0.06        -0.09     0.9286 
  2, 3             -0.07         0.03        -0.13        -0.01        -2.19     0.0335 
  2, 4              0.00         0.00         0.00         0.00          .        
Contrast               Degrees 
                       of                      P-value 
                       Freedom        Wald F   Wald F 
OVERALL MODEL                14     88506.69     0.0000 
MODEL MINUS 
  INTERCEPT                  13       113.79     0.0000 
INTERCEPT                     .          .        . 
VSTATUS                       2        16.01     0.0000 
BMIGROUP                      1       238.70     0.0000 
PIR                           2         4.44     0.0173 
NEWAGE                        1         5.91     0.0191 
RIAGENDR * RACE               7        56.91     0.0000 
------------------------------------------------------- 
Conditional Marginal   Condition- 
  #1                   al 
                       Marginal             SE     T:Marg=0    P-value 
---------------------------------------------------------------------- 
VSTATUS 
  1                          3.89         0.01       414.94     0.0000 
  2                          3.89         0.01       554.59     0.0000 
  3                          3.95         0.01       436.90     0.0000 
---------------------------------------------------------------------- 
Contrasted 
  Conditional          CONDMARG 
  Marginal #1          Contrast             SE       T-Stat    P-value 
---------------------------------------------------------------------- 
COND_EFF Contrast #  1       0.00         0.01         0.04     0.9658 
COND_EFF Contrast #  2      -0.06         0.01        -4.46     0.0001 
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COND_EFF Contrast #  3      -0.06         0.01        -5.45     0.0000 
---------------------------------------------------------------------- 
LOGTR LINEAR REGRESSION 
Number of observations read       :  30070    Weighted count:285937478 
Observations in subpopulation     :   2191    Weighted count: 10376377 
Observations used in the analysis :   2191    Weighted count: 10376377 
Weighted mean response is 4.355361 
Multiple R-Square for the dependent variable LOGTR: 0.130919 
Response variable LOGTR: LOGTR 
For Subpopulation: TRIVITD = 1by: Independent Variables and Effects. 
----------------------------------------------------------------------------------------- 
Independent                                                                             
P-value 
  Variables and        Beta                      Lower 95%    Upper 95%                 
T-Test 
  Effects              Coeff.          SE Beta   Limit Beta   Limit Beta   T-Test B=0   
B=0 
----------------------------------------------------------------------------------------- 
Intercept         5.30         0.53         4.23         6.38         9.93     0.0000 
VSTATUS 
  1              -0.00         0.04        -0.08         0.08        -0.04     0.9705 
  2               0.03         0.03        -0.04         0.10         0.91     0.3659 
  3               0.00         0.00         0.00         0.00          .        .Six 
month time  period 
  1              -0.07         0.03        -0.13        -0.01        -2.26     0.0287 
  2               0.00         0.00         0.00         0.00          .        . 
BMIGROUP, RACE 
  1, 1           -0.94         0.53        -2.01         0.13        -1.77     0.0835 
  1, 2       .   -1.20         0.53        -2.27        -0.13        -2.25     0.0291 
  1, 3           -0.95         0.53        -2.02         0.13        -1.78     0.0822 
  1, 4           -0.96         0.52        -2.01         0.08        -1.87     0.0686 
  2, 1           -0.57         0.54        -1.67         0.52        -1.06     0.2953 
  2, 2           -0.93         0.52        -1.98         0.12        -1.78     0.0824 
  2, 3           -0.53         0.53        -1.59         0.53        -1.01     0.3195 
  2, 4            0.00         0.00         0.00         0.00          .        . 
-------------------------------------------------------------------------- 
Contrast               Degrees 
                       of                      P-value 
                       Freedom        Wald F   Wald F 
------------------------------------------------------- 
OVERALL MODEL                11     14864.72     0.0000 
MODEL MINUS 
  INTERCEPT                  10        44.33     0.0000 
INTERCEPT                     .          .        . 
VSTATUS                       2         0.59     0.5595 
RIDEXMON                      1         5.11     0.0287 
BMIGROUP * RACE               7        45.43     0.0000 
------------------------------------------------------- 
Conditional Marginal#1 Conditional                      
                       Marginal             SE     T:Marg=0    P-value 
---------------------------------------------------------------------- 
VSTATUS 
  1                          4.34         0.03       165.30     0.0000 
  2                          4.38         0.02       175.73     0.0000 
  3                          4.35         0.03       146.47     0.0000 
---------------------------------------------------------------------- 
Contrasted 
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  Conditional          CONDMARG 
  Marginal #1          Contrast             SE       T-Stat    P-value 
---------------------------------------------------------------------- 
COND_EFF Contrast #  1      -0.03         0.04        -0.88     0.3859 
COND_EFF Contrast #  2      -0.00         0.04        -0.04     0.9705 
COND_EFF Contrast #  3      0.03         0.03         0.91     0.3659 
---------------------------------------------------------------------- 
BPSY LINEAR REGRESSION 
Number of observations read       :  30070    Weighted count:285937478 
Observations in subpopulation     :   4513    Weighted count: 21903379 
Observations used in the analysis :   4513    Weighted count: 21903379 
Weighted mean response is 108.411819 
Multiple R-Square for the dependent variable BPSY: 0.157109 
Response variable BPSY: average systolic 1 reading (mm/Hg) 
For Subpopulation: BPSYVITD = 1by: Independent Variables and Effects. 
----------------------------------------------------------------------------------------- 
Independent                                                                             
P-value 
  Variables and        Beta                      Lower 95%    Upper 95%                 
T-Test 
  Effects              Coeff.          SE Beta   Limit Beta   Limit Beta   T-Test B=0   
B=0 
----------------------------------------------------------------------------------------- 
Intercept          106.96         1.21       104.53       109.40        88.50     0.0000 
VSTATUS  1         1.99         0.63         0.71         3.26         3.13     0.0031 
  2                0.70         0.54        -0.39         1.79         1.30     0.2011 
  3                0.00         0.00         0.00         0.00          .        . 
BMIGROUP 
  1               -6.64         0.51        -7.67        -5.61       -12.98     0.0000 
  2                0.00         0.00         0.00         0.00          .        . 
NEWAGE             1.14         0.10         0.93         1.34        11.06     0.0000 
Gender, RACE 
  1, 1             8.56         1.12         6.30        10.82         7.63     0.0000 
  1, 2             9.66         1.10         7.44        11.87         8.79     0.0000 
  1, 3             7.60         1.21         5.15        10.04         6.26     0.0000 
  1, 4             7.85         1.68         4.47        11.24         4.67     0.0000 
  2, 1             4.09         1.16         1.75         6.43         3.52     0.0010 
  2, 2             4.72         1.12         2.47         6.97         4.23     0.0001 
  2, 3             3.59         1.16         1.25         5.93         3.09     0.0034 
  2, 4             0.00         0.00         0.00         0.00          .         
 
Contrast               Degrees 
                       of                      P-value 
                       Freedom        Wald F   Wald F 
------------------------------------------------------- 
OVERALL MODEL                12     18780.14     0.0000 
MODEL MINUS 
  INTERCEPT                  11        78.67     0.0000 
INTERCEPT                     .          .        . 
VSTATUS                       2         5.14     0.0098 
BMIGROUP                      1       168.36     0.0000 
NEWAGE                        1       122.36     0.0000 
RIAGENDR * RACE               7        65.59     0.0000 
------------------------------------------------------- 
Conditional Marginal   Condition- 
  #1                   al 
                       Marginal             SE     T:Marg=0    P-value 
98 
 
 
 
---------------------------------------------------------------------- 
VSTATUS 
  1                        109.54         0.53       208.47     0.0000 
  2                        108.26         0.40       269.69     0.0000 
  3                        107.56         0.39       274.75     0.0000 
---------------------------------------------------------------------- 
COND_EFF Contrast #  1      1.28         0.54         2.39     0.0211 
COND_EFF Contrast #  2      1.99         0.63         3.13     0.0031 
COND_EFF Contrast #  3      0.70         0.54         1.30     0.2011 
---------------------------------------------------------------------- 
BPDI LINEAR REGRESSION 
Number of observations read       :  30070    Weighted count:285937478 
Observations in subpopulation     :   4536    Weighted count: 21964438 
Observations used in the analysis :   4536    Weighted count: 21964438 
Multiple R-Square for the dependent variable BPDI: 0.044782 
Response variable BPDI: average diastolic 1 reading (mm/Hg) 
For Subpopulation: BPDIVITD = 1 by: Independent Variables and Effects. 
Independent  P-value 
  Variables and        Beta                      Lower 95%    Upper 95%                 
T-Test 
  Effects              Coeff.          SE Beta   Limit Beta   Limit Beta   T-Test B=0   
B=0 
----------------------------------------------------------------------------------------- 
Intercept           61.79         0.58        60.61        62.96       106.34     0.0000 
VSTATUS 
  1                -0.55         0.67        -1.90         0.80        -0.82     0.4188 
  2                -0.78         0.78        -2.35         0.79        -1.00     0.3232 
  3                 0.00         0.00         0.00         0.00          .        . 
Gender  1    .     -3.22         0.51        -4.24        -2.20        -6.38     0.0000 
  2                 0.00         0.00         0.00         0.00          .        . 
NEWAGE             1.10         0.12         0.85         1.35         9.01     0.0000 
Contrast               Degrees 
                       of                      P-value 
                       Freedom        Wald F   Wald F 
 
OVERALL MODEL                 5      8339.62     0.0000 
MODEL MINUS 
  INTERCEPT                   4        38.22     0.0000 
INTERCEPT                     .          .        . 
VSTATUS                       2         0.51     0.6013 
RIAGENDR                      1        40.65     0.0000 
NEWAGE                        1        81.23     0.0000 
 
Conditional Marginal   Condition- 
  #1                   al 
                       Marginal             SE     T:Marg=0    P-value 
VSTATUS 
  1                         59.62         0.47       127.16     0.0000 
  2                         59.39         0.56       106.35     0.0000 
  3                         60.17         0.55       108.76     0.0000 
Contrasted 
  Conditional          CONDMARG 
  Marginal #1          Contrast             SE       T-Stat    P-value 
---------------------------------------------------------------------- 
COND_EFF Contrast #  1    0.23         0.58         0.40     0.6920 
COND_EFF Contrast #  2   -0.55         0.67        -0.82     0.4188 
COND_EFF Contrast #  3   -0.78         0.78        -1.00     0.3232 
---------------------------------------------------------------------                        
